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Signaling Induced by Inflammatory Mediators in the Rodent Pulmonary
Microvasculature
Abstract
Acute lung inflammation (ALI), stemming from a disproportionate and detrimental immune response, may
arise from or complicate other disease states, leading to the often-fatal acute respiratory distress
syndrome (ARDS). Because of the many culpable factors and differing points of induction, pinning down
the signaling mechanisms involved in the morbidity of this disorder as well as defining an effective
treatment has proved problematic. However, the most detrimental characteristic of this condition is seen
regardless of the development of the response: increased microvascular permeability. Because of the
architecture and the size of the pulmonary microvascular network, the lungs have a resident, sequestered
population of leukocytes that are able to rapidly respond to injury or infection, but may also contribute to
the pathology of ALI/ARDS by increasing endothelial barrier dysfunction. Many inflammatory mediators
dictate the course and gravity of the response by inducing endothelial cytoskeletal reorganization, such as
induction of actin stress fibers, cell rounding and contraction, and dissociation of interendothelial
junctions.
Thrombin is a well-studied mediator that has been shown to be barrier-disruptive rapidly increases
microvascular permeability. Sphingosin-1-phosphate (S1P) is a more novel, less understood mediator that
has been shown to mediate basal vascular permeability as well as to enhance barrier integrity in
inflammation. Inflammatory signaling may also expand throughout the lungs through intercellular
communication via gap junctions composed of connexins, such as Connexin 43 (Cx43). Herein, we
explored how intercellular communication through Cx43-containing gap junctions mediates thrombininduced signaling as well as the interplay between thrombin- and S1P- induced signaling on the
pulmonary microvascular barrier.
We isolated and perfused lungs from rats and mice, a physiologically-relevant model to study lung
inflammation. We found that focal micropuncture instillations of thrombin were able to induce responses
related to hyperpermeability (including, changes in intracellular Ca2+, increased F-actin polymerization,
and increased reactive oxygen species generation) both in microvessels directly treated with thrombin
and those far outside the instilled region (up to 1000 μm away), and the expansion of signaling into the
untreated microvessels was due to intercellular communication mediated by Cx43. For the F-actin
polymerization response, we determined that the specific second messenger being communicated and
propagating the thrombin-induced increase was inositol trisphosphate (IP3). We also found that, though
thrombin induced increases in mean Ca2+in cultured cells, it instead induced increases in the amplitude
of cytosolic Ca2+ oscillations in pulmonary microvessels. While we observed that untreated primary
pulmonary microvascular endothelial cells and pulmonary microvessels from mice lacking endothelial
Cx43 displayed higher levels of the S1P receptor, S1P2, thrombin induced an increase in S1P2 expression
that was dependent on the presence of Cx43. While S1P itself was able to partially rescue barrier integrity
following thrombin treatment, we show for the first time that S1P2 signaling substantially contributes to
thrombin-induced endothelial hyperpermeability, and that inhibiting S1P2 significantly reduced thrombininduced permeability increases.
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ABSTRACT
Acute lung inflammation (ALI), stemming from a disproportionate and
detrimental immune response, may arise from or complicate other disease states, leading
to the often-fatal acute respiratory distress syndrome (ARDS). Because of the many
culpable factors and differing points of induction, pinning down the signaling
mechanisms involved in the morbidity of this disorder as well as defining an effective
treatment has proved problematic. However, the most detrimental characteristic of this
condition is seen regardless of the development of the response: increased microvascular
permeability. Because of the architecture and the size of the pulmonary microvascular
network, the lungs have a resident, sequestered population of leukocytes that are able to
rapidly respond to injury or infection, but may also contribute to the pathology of
ALI/ARDS by increasing endothelial barrier dysfunction. Many inflammatory mediators
dictate the course and gravity of the response by inducing endothelial cytoskeletal
reorganization, such as induction of actin stress fibers, cell rounding and contraction, and
dissociation of interendothelial junctions.
Thrombin is a well-studied mediator that has been shown to be barrier-disruptive
rapidly increases microvascular permeability. Sphingosin-1-phosphate (S1P) is a more
novel, less understood mediator that has been shown to mediate basal vascular
permeability as well as to enhance barrier integrity in inflammation. Inflammatory
signaling may also expand throughout the lungs through intercellular communication via
gap junctions composed of connexins, such as Connexin 43 (Cx43). Herein, we explored
how intercellular communication through Cx43-containing gap junctions mediates
thrombin-induced signaling as well as the interplay between thrombin- and S1P- induced
signaling on the pulmonary microvascular barrier.
We isolated and perfused lungs from rats and mice, a physiologically-relevant
model to study lung inflammation. We found that focal micropuncture instillations of
thrombin were able to induce responses related to hyperpermeability (including, changes
in intracellular Ca2+, increased F-actin polymerization, and increased reactive oxygen
species generation) both in microvessels directly treated with thrombin and those far
outside the instilled region (up to 1000 μm away), and the expansion of signaling into the
untreated microvessels was due to intercellular communication mediated by Cx43. For
the F-actin polymerization response, we determined that the specific second messenger
being communicated and propagating the thrombin-induced increase was inositol
trisphosphate (IP3). We also found that, though thrombin induced increases in mean
Ca2+in cultured cells, it instead induced increases in the amplitude of cytosolic Ca2+
oscillations in pulmonary microvessels. While we observed that untreated primary
pulmonary microvascular endothelial cells and pulmonary microvessels from mice
lacking endothelial Cx43 displayed higher levels of the S1P receptor, S1P2, thrombin
induced an increase in S1P2 expression that was dependent on the presence of Cx43.
While S1P itself was able to partially rescue barrier integrity following thrombin
treatment, we show for the first time that S1P2 signaling substantially contributes to
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thrombin-induced endothelial hyperpermeability, and that inhibiting S1P2 significantly
reduced thrombin-induced permeability increases.
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CHAPTER 1.

INTRODUCTION

Lung Inflammation
Although unchecked inflammation leading to endothelial barrier disruption can be
detrimental throughout the body, inflammation in the lungs can be particularly hazardous
and life threatening. Acute lung inflammation (ALI), and its more grave form acute
respiratory distress syndrome (ARDS), results from extensive inflammation in the lungs
that is associated with increased microvascular permeability, alveolar flooding, and
impaired gas exchange[1, 2]. While these conditions have been extensively studied,
ARDS maintains a high morbidity and mortality rate, particularly in critically ill patients
where this severe lung inflammation occurs secondary to other conditions, such as sepsis,
shock, or high-risk surgery [3, 4]. Despite advancements in understanding of the
pathophysiology ALI/ARDS, advancements in treatment have been sparse. The incidence
in intensive care unit patients and mortality of ARDS has not significantly lessened since
it was first described in 1967[3, 5, 6]. Treatment is largely supportive, dependent on
symptom management and mechanical ventilation, and, due to the heterogeneity in the
development and presentation of severe pulmonary inflammation, pharmacological
interventions are lacking [6-8]. Understanding the development and progression of this
injurious condition, specifically within the pulmonary microvasculature, has been and
remains crucial to combating this hyperinflammatory event.
Pulmonary Vasculature
The endothelial barrier is composed of a monolayer of endothelial cells in close
association with one another through interendothelial junctions, specifically adherens
junctions (AJs) and tight junctions (TJs), formed through the homotypic association of
the protein components in the plasma membrane of adjacent endothelial cells[9]. The
semi-permeability of the endothelial barrier is due to the presence of these
interendothelial junctions which allow the endothelium to regulate the paracellular
passage of small molecules[10]. AJs, which account for approximately 80% of
interendothelial junction complexes, are formed from the interaction of vascular
endothelial cadherin (VE-cadherin) proteins between neighboring endothelial cells; TJs
are similarly composed of members of either the occludin or claudin protein families [4,
9]. AJs, as well as TJs, are able to associate with the cytoskeleton via members of the
actin-binding protein families catenins and zonula occludens, respectively[10]. In the
normal pulmonary endothelium, cytoskeletal tethering forces within and between
endothelial cells help to maintain the tight vascular barrier, and the association between
VE-cadherin and the cortical actin band helps to strengthen the AJs[1, 9]. However, in
inflammation, cytoskeletal rearrangement and formation of actin stress fibers leads to
endothelial cell contraction and the disruption of AJs, which promotes formation of
interendothelial gaps and an increase in permeability[9].

1

Compared to other organ systems, the lungs possess the highest ratio of
endothelial cells to other resident cell types[11]. This is due to the large, dense capillary
network required for the gas exchange that takes place here. In the alveolar capillaries,
the endothelial cells are particularly thin and are typically separated from the airway cells
only by the basement membrane[12]. In addition, the pulmonary capillaries are generally
narrower than what is seen in the systemic vasculature and are subject to lower perfusion
pressures [11, 13, 14]. Because of this specific organization in the lung, under normal
conditions there remains a large pool of leukocytes, including neutrophils, monocytes,
and lymphocytes, within the microvasculature, and this allows for a more rapid immune
response during inflammation[15]. However, also because of the organization of the lung
capillaries, these marginated immune cells may wreak havoc on the endothelium during
inflammation, releasing pro-inflammatory mediators and toxic oxidant species that
contribute to endothelial apoptosis and increased permeability [1, 16]. As a short
diffusion distance is essential for adequate oxygenation of blood flowing in pulmonary
capillaries, increased permeability and edema in these tissues carries severe body-wide
consequences.
Initiation of Lung Inflammation
Given that the airways are directly and continuously exposed to the environment,
as well as the size and proximity of the vasculature, this substantial population of
endothelial cells are particularly vulnerable to infection and injury [1]. Lung
inflammation, including the cases that proceed to ALI and ARDS, may be initiated
through two routes, either direct or indirect injury to the lung [1, 6, 17]. Because of the
assortment of different conditions and insults that can have lung inflammation as an end
result, it is difficult to outline the particular events leading up to the more fatal cases [17].
However, the defining and most critical characteristic is the increased pulmonary
microvascular permeability, and the other major side effects of alveolar flooding,
decreased gas exchange, and lung edema, are either a result of or worsened by this
principal dysfunction [10, 18, 19]. See Table 1-1 for a list of various causes of severe,
detrimental lung inflammation.
Two major events that may lead to severe lung inflammation are sepsis and injury
caused by mechanical ventilation. Sepsis is the systemic inflammatory response to
infection, and is the most prevalent cause of ICU deaths that has ALI/ARDS as a
comorbidity [8, 20-24]. In infection, pathogen-associated molecular patterns (PAMPs),
typically consisting of bacterial or fungal cell wall components, are recognized by
pattern-recognition receptors (PRRs) expressed on various cell types, including
endothelial. [25-27]. The best studied examples of these are the PAMP
lipopolysaccharide (LPS) which is recognized by the PRR toll-like receptor 4 (TLR4).
Lung inflammation and sepsis go hand-in-hand: while Gram-negative sepsis is the most
common cause of ARDS, bacterial pneumonia may also cause sepsis [19, 28, 29]. Cecal
ligation and puncture (CLP) models of sepsis have shown that there is an upregulation of
the RhoA effector protein Rho kinase 1 (ROCK1), which can contribute to increased
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Table 1-1.

Direct and indirect causes of severe lung inflammation

Direct
Infectious pathogens (ex.
lipopolysaccharide)[7, 30]
Aspiration injury[8, 17, 22, 30]
Allergens[30]
Toxic gases[8, 30]
Barotrauma/Volutrauma[30]
Mechanical ventilation injury[8, 22, 30]
Pneumonia[7, 8, 17, 22]
Lung contusions[8, 22, 30]
Airway obstruction[8]
Fat emboli[22]

Indirect
Ischemia/reperfusion[2]
Pancreatitis[8]
Severe burns[8]
Mass transfusion[8, 22]
Sepsis[2, 4, 7, 17, 22, 31]
Severe trauma/Shock[8, 17, 22]
Drug reactions/overdose[8, 22]
Multiple/long bone fractures[8]
Cardiopulmonary bypass[8]
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microvascular permeability by disrupting AJs and endothelial cell contraction [10, 32,
33]. There is also increased activation of the coagulation cascade in sepsis, which may
contribute to microthrombus formation and microvascular occlusion [2, 10].
While mechanical ventilation is a major intervention in treating many critical
illnesses, it may worsen or even cause severe lung inflammation and injury in what is
termed ventilator-induced lung injury (VILI) [8, 29]. In the past, mechanical ventilation
was given with high tidal volumes, which has been shown to induce pro-inflammatory
responses, leading to an increase in adhesion molecules on lung microvascular
endothelial cells, as well as over-inflation of the alveoli [22, 30]. In one study in mice
infected with Streptococcus pneumoniae, mechanical ventilation resulted in increased
lung permeability and decreased blood oxygenation compared to mice with pneumonia
alone [29]. In cases where inflammation in the lung has already progressed to the point
that there is increased vascular permeability or edema, blood flow in the area may be
compromised to the point which mechanical ventilation yields ventilation-perfusion
mismatch [1]. This ventilator dead space contributes to the over-inflation of the lungs
such that the endothelial cells become stretched, damaging both already inflamed tissues
as well as unaffected areas [1, 8]. However, low tidal volumes also carry risks because of
the necessary increase in respiratory rates that may lead to hypercapnia [22, 29]. Current
strategies to prevent VILI involve low tidal volume with high positive end-expiratory
pressure (PEEP), which combined help to mitigate overstretch injury as well as the
collapse of alveoli [8, 34-36].
Mechanisms of Endothelial Barrier Dysfunction
A major path through which increased permeability is achieved is through
endothelial cytoskeletal remodeling. Inflammatory mediators induce endothelial
activation, which often includes the involvement of Rho family GTPases, RhoA and
Rac1 [9, 37]. In healthy endothelium, Rac1 is the predominant active GTPase regulating
the actin cytoskeleton in a barrier-protective manner, mediating the stability of the
cortical actin band as well as the association between the actin cytoskeleton and the
AJs/TJs[9]. In disease states, inflammatory mediators induce the activation of the RhoA,
and its downstream effector ROCK, which affects actin dynamics in a barrierdestabilizing manner [9, 10]. In addition to promoting actin stress fiber formation over
cortical actin band formation, RhoA induces endothelial cell contraction and rounding
[10, 37]. Hepatocyte growth factor (HGF) induces the activation of Rac1, and in a two-hit
model of ALI (induction of VILI and treatment with thrombin), treatment with HGF
decreased lung vascular leak and infiltration of immune cells into lung tissue [38]. ExoS
and ExoT, the cytotoxins responsible for increases in permeability associated with
Pseudomonas aeruginosa-induced lethal pneumonia, were found to significantly decrease
Rac1 activation and increase RhoA activation within 10 minutes of treatment in lung
endothelial monolayers [39].
Inflammatory mediators, particularly those activating G-protein coupled
receptors, will also induce an increase in intracellular Ca2+ through the emptying of

4

internal Ca2+ stores [40]. This emptying of Ca2+ stores is able to, in turn, stimulate
external calcium entry through the activation of transient receptor potential canonical
(TRPC) channels [9] A major TRPC protein in the endothelium is TRPC6. LPS
activation of TLR4 subsequently leads to an increase in Ca2+, and LPS airway instillation
was unable to induce increases in lung permeability in a TRPC6 knockout mouse line
[41].The increase in Ca2+ leads to the Ca2+/calmodulin dependent activation of myosin
light chain kinase (MLCK), which phosphorylates myosin II [37]. Through this the
actomyosin motor is activated which increases intracellular tension through the crossbridging interactions between actin and myosin fibers. This subsequently results in the
pulling apart of the interendothelial junctions and contributes to the rounding of
endothelial cells [9, 37].
In addition to the changes to the cytoskeleton due to endothelial cell activation by
pro-inflammatory mediators, damage caused by leukocytes is also a major contributor to
increases in microvascular permeability. As explained earlier, the unique architecture of
the lung capillary network creates an environment where leukocytes (specifically
neutrophils) may become marginated and is also the site of leukocyte migration into
targeted tissues. In normal endothelium, there is some baseline expression of adhesion
molecules but intravascular shear forces and the endothelial glycocalyx prevent leukocyte
adhesion as well as adhesion molecules exposure; in inflammation, however, activated
endothelial cells upregulate production of chemokines and adhesion molecules (such as
P-selectin, E-selectin, and ICAM1) presented on the luminal surface and various proinflammatory mediators also initiate loss of proteins composing the glycocalyx, further
exposing the adhesion molecules[1, 13, 42-45]. Increases in these responses result in
recruitment and accumulation of leukocytes at the targeted tissues [24, 44].
Traditionally, the steps in leukocyte movement across the endothelial barrier are
rolling, adhesion, and diapedesis. Neutrophils, however, are typically wider than the
pulmonary capillary diameter, and they must undergo a shape change to pass through
[11-13]. Activation of the neutrophils during inflammation only increases their stiffness
and therefore the transit time through the microvasculature [13, 40]. For this reason,
while other systemic beds see neutrophil extravasation primarily in post-capillary
venules, in the lungs this is primarily observed in the capillaries, and rolling is not
thought to occur in this transendothelial migration [11, 26, 40, 42]. Neutrophils trapped in
these capillaries can result in microvascular blockage and contribute to hyperpermeability
through the release of cytotoxic agents, such as reactive oxygen species (ROS),
antimicrobial peptides, proteases, and lytic enzymes [46, 47]. In addition, neutrophils
have been shown to undergo a specific type of cell death in which they extrude neutrophil
extracellular traps (NETs): nuclear DNA strands in web-like structures that act to entrap
pathogens [47, 48]. NETs have been shown to further induce cytotoxicity and endothelial
cell death, in addition to contributions to permeability and microvascular occlusion [47].
In one study of transfusion-related ALI, antibodies directed against histones (a
component of NETs) lead to reduced lung edema and mortality[48]. In sepsis, depletion
of neutrophils has been shown to be protective to the lungs [1, 13, 26]. In one influenza
model of ALI, neutrophil-depleted mice showed no signs of respiratory distress or
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development of NETs [49]. Thus, while immune cells are necessary for recovery,
overzealous activation of leukocytes may exacerbate inflammation.
Common Inflammatory Mediators Affecting Microvascular Permeability
While there are many causes and factors that may precede lung inflammation, the
signaling involved is often initiated by the same common inflammatory mediators.
In inflammation, the coagulation cascade is activated and leads to the production
of thrombin at sites of pulmonary microembolism [1, 50]. Within the coagulation
cascade, the serine protease thrombin cleaves fibrinogen to fibrin, allowing for fibrin
deposition and clotting [2, 51, 52]. Thrombin binds protease-activated receptor-1 (PAR1), a G-protein coupled receptor [50]. Activation of PAR-1 leads to generation of inositol
trisphosphate (IP3), which then binds its receptors at the endoplasmic reticulum (ER) and
causes ER store Ca2+ release as well as subsequent external Ca2+ entry.. This increase in
intracellular calcium has been shown to underlie the thrombin-induced actions of
endothelial cell contraction, increased microvascular permeability, and increased actin
polymerization and stress fiber formation [53, 54]. In addition, activation of PAR-1 by
thrombin also induces activation of NADPH oxidase 2 (Nox2), leading to the production
of ROS, and activation of RhoA, both of which further contribute to thrombin-induced
disruption of AJs and increases in barrier permeability [10, 51].
LPS, as mentioned earlier, is an essential component of Gram-negative bacterial
cell walls (ex: Escherichia coli) that is recognized by and activates TLR4 on endothelial
cells [41, 55]. TLR4 activation has been shown to induce the decreased expression of
VE-cadherin and the disruption of AJs, and initiates the activation of pro-inflammatory
signaling pathways leading to cytokine expression and microvascular barrier disruption
through RhoA/ROCK activation [19, 41, 56] In a study using human microvascular
endothelial cells in culture, inhibiting ROCK prevented the LPS-induced MLC
phosphorylation and decrease in transendothelial resistance [10]. In an in vivo study in
which LPS was injected intravenously to induce ALI, blocking ROCK attenuated both
LPS-induced lung edema and neutrophil emigration [33]. Another pro-inflammatory
mediator that induces endothelial barrier disruption is tumor necrosis factor alpha
(TNFα). TNFα is an early inflammatory cytokine that activates its receptor TNFR1 on
endothelial cells [19, 45, 57]. TNFα induces expression of other inflammatory mediators
(such as ICAM1, IL-1β, and IL-8) through activation of the transcription factor NF-κB,
as well as induces the degradation of the endothelial glycocalyx through the activation of
heparanase [45, 57]. In endothelial cells, TNFα can also induce the formation of actin
stress fibers [26]. While the concentration of TNFα in BAL fluid has been shown to
correlate with the development of ALI/ARDS, a clinical trial of a monoclonal antibody
directed against it did not show improved survival rates [58, 59].
One example of a barrier-protective inflammatory mediator is cyclic adenosine
monophosphate (cAMP) [9]. cAMP is a second messenger generated from ATP by
adenylate cyclase (AC) at the plasma membrane and is degraded by phosphodiesterases.
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cAMP has been shown to stabilize the cortical actin ring and strengthen interendothelial
junctions, and decrease or prevent the expression of pro-inflammatory cytokines, leading
to increased endothelial barrier integrity in inflammation[28]. Pretreatment with the AC
activator forskolin significantly decreased the ability of LPS to induce hyperpermeability
in human lung microvascular endothelial cells in culture [55]. In a CLP-sepsis induction
of ALI, increases in permeability could be blocked by using a phosphodiesterase inhibitor
[60]. While generation of cAMP at the membrane induces barrier-protective effects, lung
microvascular endothelial cells also express a soluble form of AC (AC10) that exists in
the cytosol [28]. Activation of AC10 has been shown to induce increased microvascular
permeability and may be stimulated by the presence of bicarbonate. In one ex vivo model
of LPS-induced lung inflammation, increases in permeability could be prevented with the
use of an AC10 inhibitor or removal of bicarbonate from the perfusate [28].
Sphingosine-1-phosphate (S1P) is a lysophospholipid signaling molecule that is
involved in the regulation of a multitude of cellular processes including embryonic
vascular development, cell proliferation and motility, angiogenesis, and immune and
allergic responses [61-65]. The expression of S1P, as well as its receptors and enzymes
involved in its synthesis, has been found to be increased in inflammation and cancer [65,
66]. S1P is derived from the deacetylation of ceramide to sphingosine, followed by
phosphorylation by sphingosine kinase (SphK) [67].Two isoforms of SphK exist, SphK1
and SphK2, with SphK1 being the most abundant as well as the rate-limiting enzyme in
S1P synthesis [62, 67]. The receptors for S1P are a family of G-protein coupled receptors
(S1P1-5) that are expressed in a variety of cell types, particularly in endothelial cells [62].
S1P1 is the predominate receptor in endothelial cells, and is by far the most extensively
studied [68]. One of the main contributions of S1P1 in endothelial cells is enhancement
of the endothelial barrier. S1P1 signals exclusively through Gαi, resulting in activation of
Rac1 [61, 69]. This leads to enhancement of the endothelial barrier through translocation
of VE-cadherin to AJs, cytoskeletal rearrangement, and subsequent spreading of
endothelial cells to close interendothelial gaps [37, 61]. In contrast, S1P2, another S1P
highly expressed receptor in endothelial cells, signals through Gαi as well as Gαq and
Gα12/13, which leads to preferential activation of RhoA over Rac1 [61, 69]. This evokes
opposite, barrier destructive effects of disruption of AJs, endothelial cell contraction, and
induction of actin stress fibers [9, 37, 61]. Because of the opposing responses following
activation of the two S1P receptors, the balance of S1P1 and S1P2 signaling is said to
maintain vascular tone [66, 70, 71]. However, because of the larger role of the S1P1
receptor, S1P is generally considered a barrier-supportive inflammatory mediator [62].
Expansion of Inflammatory Signaling
Excessive inflammation can spread outside of the injured or infected tissues to
surrounding healthy tissues [72]. This expansion of inflammatory signaling can be
observed in ARDS. One of the requirements for a diagnosis is the presence of bilateral
infiltrates in the lungs, observed in chest radiographs as opacities in both lungs [3, 7, 73].
This suggests that not only is inflammation spreading throughout a lung, but also that this
signaling is able to spread between the two lungs. While the reason for this spread of
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inflammation is unclear, recent evidence points to the movement of second messengers
through gap junctions as the causative mechanism.
Gap junctions facilitate the direct exchange of ions and small molecules between
adjacent cells [74]. They are composed of connexin subunits; 6 connexins form 1
hemichannel or connexon, and connexons from two adjacent cells form the functioning
gap junction channel [75]. Gap junctions are known to allow the propagation of signaling
molecules in a variety of cell types [76-78]. In pulmonary endothelium, Connexin 43
(Cx43) is abundantly expressed and has been shown to be the major connexin involved in
the spread of inflammatory signaling. Increases in endothelial permeability induced by
the inflammatory mediators, thrombin and LPS occurred in tandem with increases in
Cx43 expression, and inhibiting intercellular communication through gap junctions
mitigates the increases in permeability [56, 79-81]. Cx43-containing gap junctions clearly
contribute to the spatial expansion of inflammatory signaling, and as more is elucidated
as to the exact mechanisms involved in this propagation of signaling, such as specific
second messengers involved, new and more-effective therapies may be developed to limit
it.
Specific Aims
For as much as has been studied on this ubiquitous inflammatory event, the many
gaps of that knowledge allow severe lung inflammation to remain an often deadly
condition. Increased microvascular permeability has been shown to be the most common
symptom, regardless of etiology. However, many of the traditional methods of studying
the specific responses within the endothelium are unable to adequately capture or
illustrate the mechanism behind endothelial monolayer disruption. To that end, the goal
of this project is to study signaling induced by inflammatory mediators in a
physiologically relevant model to elucidate signaling molecules involved in the
hyperpermeability response. This will be specifically addressed by employing the
isolated perfused rodent lung model to:
1. Define spatially-expansive, barrier-disruptive signaling induced by thrombin
2. Determine specific second messengers mediating this spatial expansion
3. Explore the interplay between signaling induced by both thrombin and S1P
These points will all be addressed in the following with the intention of identifying
previously unknown mechanisms by which excessive inflammatory responses may be
curtailed.
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CHAPTER 2.

THE ISOLATED PERFUSED RODENT LUNG MODEL

The majority of what we know about inflammatory signaling processes comes
from studies done in cell cultures. Barrier permeability in particular lends itself easily to
experiments using endothelial monolayers grown on transwell inserts, allowing for
precise measurement of the passage of molecules from the apical to basal compartments.
There are numerous advantages to studying inflammatory signaling in cells: there are
established cell lines readily available; cell culture itself is relatively easy and
inexpensive; and a large scale of results may be obtained in a short amount of time.
However, both the conditions in which cells are cultured and the results obtained therein
may not always coincide with in vivo observations. Cultured endothelial cells may lose
their phenotype with successive passages and are missing the interactions with other cell
types within their respective tissues [18]. In addition, some studies rely on endothelial
cells that originate from completely different organs, such as using HUVECs to make
determinations about lung inflammation [82-85]. In short, there is a vacuum for more
physiologically-relevant methods.
One such solution for this would be studies employing intravital microscopy of
the lung, in which a sedated and anesthetized animal has a transparent window implanted
in their thoracic cavity allowing for imaging [31]. However, imaging with this specific
technique is complicated by the constant movement of the lungs, due to blood flow and
ventilation. However, these obstacles are removed in the isolated perfused lung (IPL)
model. IPL is an ex vivo model in which the lungs are surgically removed from the
animal, perfused at a constant rate, and kept constantly inflated [31, 86]. Maintaining
continuous physiological pressures in the airways and vasculature allows for a highly
stable surface that is well-suited for imaging, and the results gained from this model more
closely mimic in vivo observations compared to monolayer studies [84, 86].
Surgery and Set Up
Prior to surgery, the perfusion system is set up at the microscope, and the
perfusate media (used to supplement the collected, autologous blood) is warmed to 37°C.
After sedating and anesthetizing the rat or mouse, the trachea of the rodent is cannulated.
Next, the skin covering the chest is removed. Heparin is injected directly into the heart
(.5-1mg), allowed to circulate for approximately 30 seconds, and then the nowheparinized blood is collected through the same syringe. Following this, either the ventral
chest wall is severed longitudinally and kept open with a rib separator (in the rat), or the
ribs are cut away entirely (in the mouse). Incisions are made in the heart first below the
opening of the pulmonary artery and then at the apex of the heart. Through these
incisions cannulae are placed in the pulmonary artery and into the left atrium,
respectively. Finally, the trachea is severed above the cannula, and the lungs and heart are
excised. They are then placed in a dish containing gauze that has been pre-wet with
saline. This dish is then transferred to the microscope and perfusion system.

9

Immediately following transfer, the pulmonary artery and left atrial cannulae are
connected to the perfusion tubing and the tracheal cannula is connected to a separate
airway tubing. Prior to the start of perfusion, the lungs are inflated with room air. The
collected blood is added into the pre-warmed perfusate media, and the peristaltic pump
(which evenly and continuously directs flow through the pulmonary artery cannula and
out the left atrial cannula) is started (Figure 2-1). The perfusate media used to replace or
supplement the autologous blood, in addition to being pre-warmed, also contains sugars,
physiological salts, and albumin to maintain cellular processes, pH, and permeability [86,
87].
Delivery of Dyes and Reagents to Pulmonary Microvessels
The physical stability of the IPL is ideal for microscopy studies, and this method
is often employed in real-time fluorescence imaging experiments. While fluorescent dyes
may be added directly to the perfusate, it is often more prudent to expose and image only
a section of the microvasculature. There are three main methods to accomplish this:
superfusion, catheter infusion, and micropuncture instillations.
In superfusion, a catheter connected to a syringe pump is suspended above the
lung. The reagent is then allowed to drip directly onto the lung surface (Figure 2-2).
Normally, the lung surface will be first fixed and/or permeabilized to ensure effective
distribution of dyes or antibodies to the microvessels. Catheter infusions allow for a more
controlled delivery of reagents. With this method, a microcatheter is fed through the left
atrium and wedged into the microvasculature. Because red blood cells in the
microvasculature may block or obscure fluorescence, microvessels are first cleared of
these cells by an infusion of perfusate media prior to delivery of fluorescence dyes or
reagents. (Figure 2-3). The most delicate and precise method is micropuncture
instillations. The beveled tip of a glass micropipette connected via tubing to a syringe is
used to pierce a post-capillary venule (approximately 20μm in width) (Figure 2-4). The
instilled reagent is mixed with a fluorescent dye, and the size of the instillation is viewed
through the microscope and regulated by the pressure used to compress the syringe. This
also allows for precise delineation of the microvessels receiving the substance. These
methods are sometimes used in conjunction with one another, such as first clearing a
section of the vasculature via a catheter before performing micropuncture.
In summary, IPL is an ex vivo method in which the microenvironment is
maintained to replicate different physiological parameters to what is observed in vivo.
Several techniques are employed to supply controlled and precise delivery of dyes and
reagents to pulmonary microvessels, allowing for fluorescence studies that provide
results more closely related to what is seen in the organism compared to what is observed
in cell culture studies.
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Figure 2-1. Diagram of perfusion set up in IPL
Diagram showing the isolated lungs and the flow of blood and media through the
perfusion system. Beginning at the perfusate reservoir, the blood and perfusate media
passes through the peristaltic pump. The pump thrusts the liquid forward at a constant
rate and pressure, as opposed to the pulsation pumping of the heart. The liquid then
passes through an air trap which eliminates air bubbles, thereby preventing pulmonary
embolism. The tubing section following the pump is gathered in a spiral such that the
perfusate media flowing through spends a prolonged time in the 37°C water bath. The
perfusate then is pumped into the lungs through the pulmonary artery cannula, circulates,
and then is pumped back out through the left atrial cannula. The pressure in the tubing
connected to the pulmonary artery and the left atrial cannulae, as well as the tubing
connected to the tracheal cannula, is monitored via a pressure transducer. The pressures
in the pulmonary artery, left atrial, and tracheal tubing are maintained at 3 cm H2O, 10
cm H2O, and 5 cm H2O respectively.

11

Figure 2-2. Delivery of dyes via superfusion
Image depicts set up for superfusion delivery of dyes and reagents to the mouse lung
surface. A PE10 microcatheter (white arrow) is affixed to a coverslip holder (black
arrow), and the superfusate is allowed to drip directly onto the lung tissue. Under the
microscope, the edge of the catheter may be precisely positioned to a targeted
microvascular bed at the lung surface.
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Figure 2-3. Delivery of dyes via microcatheter
Diagrams and image showing placement of microcatheter into pulmonary microvessels.
(A) Diagram depicts the placement of the PE10 microcatheter through the LA cannula.
The microcatheter is attached to a filled syringe on a pump. Inset shows cleared area
following catheter delivery of HBS. (B) Diagram depicts microcatheter wedged into a
larger vessel and delivering an infusion to all smaller, branching microvessels.
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Figure 2-4. Delivery of dyes via micropuncture
Images showing micropuncture delivery of fluorescent dye. (A) Image shows set up of
micropuncture. Here, blue light is used to identify the tip of the micropipette (black
arrows) under the microscope. (B) Confocal image following micropuncture instillation
delivery of fluorescent dye into microvasculature. Filled micropipette is visible (white
arrows). Bar – 50 μm.
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CHAPTER 3. THROMBIN INDUCES INOSITOL TRISPHOSPHATEMEDIATED SPATIALLY EXTENSIVE RESPONSES IN LUNG
MICROVESSELS*
Introduction
Compartmentalization is being increasingly recognized as a mechanism for
eliciting unique responses via a similar set of second messengers. In this regard, cellular
signaling that results from activation of plasma membrane receptors may depend on
compartmentalized regulation of second messengers. Thus, experimental models that
induce second messenger increases throughout an entire cell may be inadequate
substitutes to elucidate responses resulting from receptor-mediated increases in second
messengers.
Intercellular diffusion of second messengers, including Ca2+, IP3, cAMP, and
ATP, facilitates the induction of responses at sites remote from the stimulus site and also
coordinates responses among a larger group of cells [88-92]. The predominant second
messenger is dependent on the stimulus and defines the remote response. For example, in
lungs, remote induction of pulmonary arteriolar vasoconstriction by hypoxia is mediated
by membrane depolarization [93, 94]. In contrast, induction of P-selectin expression and
surfactant secretion in response to cell-wide increases in Ca2+ depends on intercellular
diffusion of Ca2+ [81, 90, 95]. In the latter studies that implicate Ca2+ as the diffusing
second messenger, the cell-wide Ca2+ increases were achieved by photolytic uncaging of
Ca2+ in single cells. However, since Ca2+ signaling is compartmentalized, other second
messengers may predominate in the induction of remote responses when intracellular
Ca2+ increases are elicited via activation of plasma membrane receptors. To delineate this
possibility, alternate models that activate specific plasma membrane receptors on cells
located within a spatially restricted region may need to be utilized.
In lung inflammation, a variety of inflammatory mediators activate G-protein
coupled receptors and induce the release of ER-stored Ca2+. In the case of thrombin and
PAR-1 activation, this increase in intracellular Ca2+ drives the increases in microvascular
permeability as well as F-actin formation [96-98]. Given the compartmentalization
intrinsic to Ca2+ signaling and that thrombin induces both IP3 generation and Ca2+ release,
we utilized thrombin to define the specific second messenger diffusing through
endothelial connexin-containing gap junctions.
In the lungs, the gap junction protein Cx43 is abundantly expressed, and
intercellular communication through Cx43-containing gap junctions has been shown to
-------------------*Reprinted from The American Journal of Pathology. Vol 187 /4. Rachel Escue,
Kathirvel Kandasamy, and Kaushik Parthasarathi. Thrombin Induced Inositol
Trisphosphate-Mediated Spatially Extensive Response in Lung Microvessels, 921-935,
Copyright (2017), with permission from Elsevier
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mediate the expansion of inflammatory signaling [79, 80]. In studies focusing on lung
microvessels, Cx43 has been shown to mediate the Ca2+-dependent process of surfactant
secretion and P-selectin expression as well as thrombin-induced increases in
permeability. In the case of thrombin-induced signaling, it is unclear which second
messenger is being communicated to elicit these responses. As PAR-1 activation induces
increases in IP3 and Ca2+, and Cx43 has been shown to facilitate the communication of
both, in this study we chose to investigate which specific second messenger is being
communicated in in situ pulmonary microvessels and is mediating the spatial expansion
of thrombin-induced responses [89, 90, 99]
Materials and Methods
Fluorophores and Reagents
The cell permeable Ca2+ indicators, Fura 2 AM (10 μM), Fluo 8 AM (20 μM),
Fluo4 (10 μM), and the nuclear stain Hoeschst-33342 (10μg/ml) were from Tef Labs
(Austin, TX). The F-actin marker CF488A-Phalloidin (0.5U/ml) was from Biotium
(Hayward, CA). Thrombin (5-10 U/ml), rhodamine-dextran 70 kDa (RDx70; 0.5 mg/ml),
rhodamine dextran 40kDa, (RDx40; 0.5 mg/ml) and fluorescein isothiocyate 20 kDa
(FDx20; 0.5 mg/ml) were from Sigma (St. Louis, MO). The ER Ca2+-ATPase pump
inhibitor, tert-butylhydroquinone (tBHQ; 10 μM) and ER IP3-receptor (IP3R) blocker,
Xestospongin C (XeC; 25 μM) were from EMD Millipore (Billerica, MA). Cell
permeable caged Ca2+ (NP-EGTA AM; 75 μM) and caged-IP3 (NPE-IP3; 2.5 mM) were
from Invitrogen (Grand Island, NY). The transfection reagent, Chariot (1 mg/ml) was
from Active Motif (Carlsbad, CA). The Cx43-gap junction inhibiting peptide, Gap27
(190 μM) was custom synthesized by Genemed Synthesis (San Antonio, TX).
Fluorophores and reagents were infused into microvessels in a Ca2+-rich HEPES-buffered
Ringer’s solution (HBS; 150 mM Na+, 5 mM K+, 1 mM Ca2+, 1 mM Mg2+, 10 mM
glucose, 20 mM HEPES) with 4% dextran (40 kDa) and 1% fetal bovine serum at a final
pH of 7.4. Phosphate buffered saline with Ca2+ and Mg2+ was from GE Life Sciences.
Isolated Perfused Lungs
Animals were treated in accord with protocols approved by the Institutional
Animal Care and Use Committee of the University of Tennessee Health Science Center.
Animals were given ad libitum access to food and water, and placed on a 12-h light-dark
cycle. Male Sprague-Dawley rats weighing 250-350g were purchased from a commercial
vendor. Male endothelial specific-Cx43 knockout (EC-Cx43-/-) mice on a C57BL/6J
background were bred in our animal facility, following the process previously reported
[90, 100]. Age matched floxed Cx43 (Cx43fl/fl) mice were used as controls. Isolated
blood-perfused lungs were prepared from rats and mice, as reported [101, 102]. Briefly,
animals were anesthetized by intraperitoneal injection of ketamine and xylazine. Heparin
was injected via cardiac puncture and the animals were exsanguinated. Cannulae were
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inserted into the trachea, left atrium, and pulmonary artery to inflate and perfuse blood
into the lungs, respectively. The lungs and heart were removed en bloc and transferred to
the microscope stage. The lungs were constantly inflated and continuously pumpperfused with warmed, autologous blood at 10ml/min (rat) and 2 ml/min (mouse).
Pressures in the pulmonary artery, left atrium, and airway were maintained at 10, 3, and 5
cm H2O, respectively. The lungs were kept moist with saline.
For vascular delivery of fluorophores and agents into a microvessel network, a
PE10 microcatheter was inserted through the left atrial cannula and wedged into a
microvessel. An infusion of HBS was used to establish blood-free conditions in a small
area of the lung. For delivery into single microvessels, a micropipette was filled with the
appropriate agent and then attached to a pipette holder. A micromanipulator (MO-202U;
Narishige, Japan) was used to guide the pipette holder to the vessel of interest,
micropuncture the vessel, and then instill the agent or fluorophore.
Ca2+ Imaging
In a small region of rat lungs cleared of blood, Fura2 AM was infused into
microvessels through the microcatheter for 30 minutes. After a 30 min HBS wash, the
microvessels were excited at 340 and 380 nm. Fluorescence images were continuously
captured at 515 nm either every 10 seconds or every 1 second, as indicated, using a
microscope (BX61WI, Olympus) coupled to a high sensitivity camera [103]. Following a
10-minute baseline fluorescence capture, we infused either 5 or 10 U of thrombin over
10-15 minutes. Subsequently, the microvessels were flushed with HBS, followed by a
second infusion of thrombin. For, blocking experiments, the inhibitor was infused
following the wash-off of the first thrombin infusion. Endothelial cytosolic Ca2+ was
determined using Fura2 340/380 emission ratio in 3 μm x 3 μm regions along the vessel
wall for both venules and capillaries [103].
Actin Polymerization
In a region of mouse lungs, cleared of blood using Ringer’s infusion, an alveolus
near a target venule was filled with 2% Sudan black in oil by micropuncture and acted as
a marker. The target venule was then micropunctured, and thrombin (5 U/ml) + RDx70
(0.5mg/ml) was instilled over 10 minutes. RDx70 fluorescence was used to determine the
spatial distribution of the instilled thrombin. Subsequently, the thrombin-treated and
adjacent thrombin-free regions were fixed and permeabilized by superfusing the lung
surface with 3.7% paraformaldehyde, followed by 0.05% Triton X-100, for 20 min each,
respectively. The superfusion solutions were delivered via a PE10 microcatheter
connected to an infusion pump (BSP-8000; Braintree Scientific, Braintree, MA). The
superfusate flow rate was maintained at 10 μl/min. The microcatheter was positioned so
that the opening was centered directly above the alveolus instilled with the Sudan Black
marker. The spread of the superfusate over the lung surface was restricted via an opening
cut in a plastic film placed over the lung surface. Following fixing and permeabilization,
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the thrombin-treated and adjacent thrombin-free regions were superfused with blocking
buffer containing 5% bovine serum albumin for 20 min. Finally, the region was treated
with CF488A-phalloidin (0.5 U/ml) [104] and Hoeschst-33342 (10μg/ml) for 20 min to
stain F-actin and nuclei, respectively. After a Ringer’s wash, the microvessels were
imaged via a confocal microscope (Zeiss LSM710). In studies used to determine the role
of Cx43, the experiments were repeated in EC-Cx43-/- mice. To inhibit IP3-dependent
responses, XeC was infused for 30 minutes prior to thrombin instillation.
During imaging, in addition to obtaining confocal images of the thrombininstilled region, images of the regions adjoining the thrombin-treated region were also
captured. The images were captured in all directions extending away from the region of
thrombin instillation. To reduce introduction of possible image artifacts by the lung
curvature and possible change in image focus due to lung movement, a z-stack of images
was captured at each x-y setting. Using this set of images, a montage, typically 1500
microns x 1500 microns was stitched. In generating the montage, image sections with the
best focus were selected from the z-stack of images. The use of different z-planes
introduced small differences in fluorescence intensity along the entire length of the
montage. CF488A-phalloidin fluorescence intensity was measured at randomly selected
sites. The intensity measurements were obtained from the z-plane in which the
measurement was in maximum focus. We typically quantified fluorescence intensity at
more than 50 sites in each direction away from the thrombin-treated region for each
experiment.
Ca2+ and IP3 Uncaging
We cleared a region of isolated rat lungs by infusing Ringer’s solution through a
left atrial microcatheter. Then, we infused either Fluo4 AM or Fluo8 AM for 30 min.
Subsequently, we either infused caged-Ca2+ (NP-EGTA) for 30 min or caged-IP3 (NPEIP3) + Chariot (1 mg/ml) for 30 min. Following a 30 min stabilization period, we
captured images of microvessel Fluo8 or Fluo4 fluorescence (1 image/s) using the upright
microscope (BX61WI). To uncage NP-EGTA or NPE-IP3, we exposed a defined region
of the microvasculature to UV illumination (355 nm; 15 s) using a UV laser system
(DPSL-355-30, RappOptoelectronic, Germany). Uncaging-induced responses in
microvessels were captured for several minutes after exposure to the UV illumination.
Microvascular Permeability
In a region cleared of blood using a microcatheter in an isolated blood-perfused
rat lung, a mixture of thrombin (5 U/ml) plus RDx70 (0.5 mg/ml) was instilled via
micropuncture over 10 minutes. RDx70 fluorescence was used to determine the
microvessel distribution of thrombin. After thrombin instillation, FDx20 was infused into
the thrombin-instilled and adjacent microvessels via the microcatheter for one hour. An
image of the FDx20 fluorescence in microvessels was taken every minute using an
upright microscope (Olympus BX61WI). After one hour, FDx20 infusion was stopped
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and replaced with HBS. Imaging was continued at one image per minute for 30 minutes.
As reported, images were used to determine the FDx20 fluorescence at random sites both
within and outside of the micropuncture instillation region [81]. The ratio of maximum
FDx20 fluorescence during the FDx20 infusion (peak) to that after a 10 minute HBS
wash (residual), termed ‘normalized fluorescence’ was used as an estimate of
microvascular permeability at the measurement sites.
Statistics
All data are reported as mean±SEM. All multiple groups were compared with
Kruskal-Wallis One Way ANOVA on Ranks followed by pair-wise multiple comparisons
by Dunn’s method. Pairs of data were analyzed using rank-sum test. Significance was set
at p<0.05.
Results
Induction of Microvascular Permeability by Thrombin
Thrombin-induced increase in fluid permeability across endothelial monolayers is
well established [84, 105, 106]. In contrast, the effect of thrombin on fluid flux across
microvessels is not clear. To determine this, thrombin was continuously instilled into rat
lung microvessels by micropuncture for 10 min (Figure 3-1A). Subsequently,
permeability of single microvessels was determined using the FDx20 residual
fluorescence method [81]. Images show that the residual FDx20 fluorescence was higher
in thrombin-treated than in Ringer’s-treated microvessels (Figure 3-1B-E). Quantifying
changes in single microvessels revealed that the normalized fluorescence was lower for
thrombin-treated microvessels (Figure 3-1F). These results indicated that thrombin
increased microvascular permeability in lung microvessels.
Microvessel Actin Stress Fiber Formation
In endothelial monolayers, thrombin-induced barrier perturbation occurs in
tandem with cytoskeletal remodeling, which includes formation of actin stress fibers
[107-109]. However, in in situ microvessels it is unclear whether thrombin-induced fluid
flux is accompanied by actin stress fiber formation. To define this, a mixture of thrombin
and RDx70 was continuously instilled for 10 min into microvessels of isolated bloodperfused Cx43fl/fl mouse lungs using a micropipette. RDx70 helped identify the blood
vessels to which the thrombin spread. Confocal images of RDx70 fluorescence captured
during the infusion procedure suggested that thrombin spread from the micropunctured
vessel into adjacent blood vessels, though the spread was restricted to microvessels
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Figure 3-1. Increases in microvessel permeability
(A) Monochrome image shows vascular distribution of rhodamine fluorescence after
instillation of thrombin (5 U/ml) + RDx70 (0.5 mg/ml) into a single microvessel of a rat
lung. Note that the mixture distributed only to a small number of microvessels. Bar - 100
μm (B, C) FDx20 (0.5 mg/ml) was infused into thrombin-treated microvessels for 60 min
followed by a Ringer’s wash. Pseudocolored images show peak (B) and residual (C)
fluorescence of FDx20 in the thrombin-treated vessels. Bar - 100 μm (D, E)
Pseudocolored images show peak (D) and residual (E) FDx20 fluorescence in Ringer’streated microvessels. Bar - 100 μm (F) Bar graph shows normalized FDx20 fluorescence
quantified in single thrombin- and Ringer’s-treated microvessels. n=3 lungs for Ringer’streated group, n=8 lungs for thrombin-treated group. *** = p < 0.001 compared to
Ringer’s response.
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located within 200 μm from the micropuncture site (Figure 3-2A). Thus, the instilled
thrombin remained localized within a small number of microvessels.
Fluorophore-tagged phalloidin is a marker for actin cytoskeleton in endothelial
monolayers [110-112]. Hence, we utilized phalloidin tagged to the fluorophore CF488A
to determine F-actin formation in in situ lung microvessels. Confocal images of untreated
microvessels of Cx43fl/fl mouse lungs indicated that the CF488A fluorescence was low at
baseline (Figure 3-2B). Images captured without labeling vessels with CF488Aphalloidin did not reveal any fluorescence, thus excluding the possibility that tissue
autofluorescence contaminated CF488A fluorescence (Figure 3-2C).
In response to instillation of PBS as vehicle control, the CF488A fluorescence in
microvessels remained similar to that at baseline (Figure 3-2D). The fluorescence was
similar in both the PBS-instilled vessels and those located outside the PBS-instilled
region. Thus, the instillation procedure by itself did not modify F-actin magnitude in
microvessels. In contrast, instillation of thrombin into microvessels resulted in a higher
vascular CF488A fluorescence (Figure 3-2E). Montages of confocal images revealed
that the CF488A fluorescence was high both in microvessels directly treated with
thrombin and also in vessels located outside the thrombin-treatment region. The high
fluorescence was evident even in microvessels located more than 1000 μm from the outer
boundary of the thrombin-treated region (Figure 3-2E). However, in vessels located at
increasing distances from the edge of the thrombin-instilled region, the fluorescence
steadily declined to baseline levels (Figure 3-2E). Quantifying the CF488A fluorescence
in thrombin-treated microvessels revealed that the fluorescence was 80% higher
compared to baseline (Figure 3-2F). In addition, in microvessels located outside the
thrombin-instilled region, the CF488A fluorescence was 60% higher compared to
baseline. The data indicate an increase in F-actin both in microvessels treated with
thrombin and in those located outside the thrombin-instilled region. Thus, thrombin
increases F-actin even in microvessels spatially remote from those directly treated with
thrombin.
Microvessels Are the Source of Thrombin-Induced Responses
Vascular instillations were used to define thrombin-mediated changes in
endothelial permeability and F-actin. To exclude the possibility that observed responses
were due to the instilled thrombin leaking into the alveolar compartment and initiating
responses in epithelial cells, thrombin was instilled with RDx40, a fluorescence marker
with a similar molecular weight as thrombin and thus, capable of closely following
thrombin distribution spatially. Confocal images of RDx40 captured post-instillation
indicated that its distribution was similar to that for RDx70 (Figure 3-3A). Moreover,
CF488A-phalloidin fluorescence changes in response to vascular thrombin instillation
was similar when either RDx70 or RDx40 was used as the marker (Figure 3-3B, E). In
additional experiments, we determined the extent to which alveolar epithelial F-actin
increased in response to thrombin. Toward this, we instilled together thrombin, RDx70,
and the nuclear marker, Hoechst 33342 into alveoli. Subsequently, we instilled
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Figure 3-2. Changes in F-actin formation in lung microvessels
(A) Confocal image composite of rhodamine fluorescence shows the vascular distribution
of thrombin (5 U/ml) + RDx70 mixture at the end of the instillation into a single
microvessel (arrowhead) in Cx43fl/fl mouse lung. (B) Confocal image shows CF488Aphalloidin fluorescence in untreated microvessels of a Cx43fl/fl mouse. Bar - 100 μm. (C)
Image shows autofluorescence in microvessels of a Cx43fl/fl mouse captured at the same
excitation and emission settings used for capturing CF488A-phalloidin fluorescence. Bar
- 100 μm. (D) A montage of confocal images shows CF488A-phalloidin fluorescence in
lung microvessels of a Cx43fl/fl mouse after PBS instillation. Arrowhead - site of PBS
instillation. Dashed line – outer boundary of PBS instillation. Bar - 100 μm. (E) Montage
of confocal images shows CF488A-phalloidin fluorescence in Cx43fl/fl mouse lung
microvessels located within and outside the thrombin-treated region. Arrowhead - site of
thrombin instillation. Dashed line - outer boundary of thrombin-treated region. Bar - 500
μm. (F) Graph shows CF488A-phalloidin fluorescence in microvessels for the various
treatments indicated. ** = p < 0.01 compared to untreated response, †† = p < 0.01, ††† =
p < 0.001, respectively compared to PBS response. Untreat - no instillation; PBS - PBS
instillation; t5 - thrombin (5 U/ml) instillation; o μm - microvessels located within the
thrombin-instilled region; 700 μm - microvessels located 700-1000 μm away from the
outer edge of the thrombin- instilled region. # sites –number of measurement sites
included in analysis. n=3 lungs for the un-instilled, n=3 for PBS-instilled and n=4 for
thrombin- instilled groups.
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Figure 3-3. Methodological controls for Thrombin-induced responses in lung
microvessels
(A) Confocal image composite shows distribution of rhodamine fluorescence in Cx43fl/fl
mouse lung microvessels following instillation of thrombin (5 U/ml) + RDx40 mixture.
Arrowhead - site of instillation. (B) Montage of confocal images show CF488Aphalloidin fluorescence in microvessels following micropuncture instillation of thrombin
(5 U/ml) + RDx40. White dashed line – outer boundary of the thrombin-instilled region.
Arrowhead - site of instillation (C,D) Thrombin (5 U/mL), RDx70, and Hoechst 33342
together were instilled into alveoli of Cx43fl/fl mouse lungs followed by instillation of
3.7% paraformaldehyde into the same alveoli. Then the thrombin-treated region was
superfused with CF488A-phalloidin, as detailed in Methods. Confocal image shows
CF488A-phalloidin fluorescence alone in the thrombin-instilled region (C). Confocal
image shows CF488A-phalloidin fluorescence with Hoechst 33342-stained nuclei (blue)
(D). Note Hoechst 33342-stained nuclei represent cells treated with thrombin. Bars - 100
μm. (E) Bar graph shows CF488A-phalloidin fluorescence following microvessel
instillation of either thrombin + RDx40 (RDX40) or thrombin + RDx70 (RDX70). (F)
Bar graph shows CF488A-phalloidin fluorescence at measurement sites in the absence of
any treatment (untreat) or after alveolar instillation of thrombin (alv instill). # sites –
number of measurement sites included in analysis. n = 3 for both groups.
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paraformaldehyde into the same alveoli, thus restricting the fixing process to the
thrombin-treated alveoli. Finally, the thrombin-treated regions were superfused with
CF488A-phalloidin. At the same imaging settings used for vascular thrombin instillation,
the CF488A-phalloidin fluorescence in response to alveolar thrombin instillation was
similar to that at baseline (Figure 3-3C, D, F). Moreover, the images revealed that the Factin levels were similar in both the thrombin-treated and -free alveoli. Taken together,
these experiments suggest that the endothelium predominantly contributed to the
observed responses to microvascular thrombin instillation.
Lack of Endothelial Cx43 Limits Actin Stress Fiber Formation
Interendothelial Cx43 gap junctions mediated P-selectin [80] expression and
endothelial permeability in microvessels located spatially remote from the site of insult
[81, 90]. To determine whether Cx43 gap junctions played a role in F-actin formation in
microvessels located outside the thrombin-treated region, we instilled thrombin in lung
microvessels of EC-Cx43-/- mice. Confocal images of CF488A-phalloidin fluorescence in
microvessels of EC-Cx43-/- mouse lungs at baseline reveal that the fluorescence was
similar to that in Cx43fl/fl mouse lung microvessels at baseline. (Figure 3-4A). Further,
the images also show that thrombin treatment resulted in only a small increase of
CF488A-phalloidin fluorescence in EC-Cx43-/- mouse lungs (Figure 3-4B).
Quantifying CF488A fluorescence in single microvessels revealed that in ECCx43 mice, thrombin instillation resulted in a 20%, but insignificant, increase in the
fluorescence compared to that in Ringer’s-instilled microvessels (Figure 3-4C).
Moreover, in microvessels located outside the thrombin-treated region, the CF488A
fluorescence remained at baseline levels. This lack of increase in CF488A fluorescence
was in direct contrast to that observed in Cx43fl/fl mouse lung microvessels. Thus, the data
suggest that the thrombin-induced increase in F-actin in microvessels was blunted in the
absence of endothelial Cx43.
-/-

Inhibiting Endothelial ER Ca2+ Release Limits Actin Stress Fiber Formation
Thrombin causes release of Ca2+ from ER stores, which has been indicated to
underlie F-actin formation in endothelial monolayers [98, 113, 114]. Hence, we
determined whether the increase in F-actin in mouse lung microvessels was dependent on
ER store Ca2+ release. Toward this, ER Ca2+ release was inhibited using XeC, an
established inhibitor of IP3R on ER [103, 115, 116]. XeC was infused into microvessels
in a small region of Cx43fl/fl mouse lungs via a venous microcatheter. Subsequently,
thrombin was instilled by micropuncture into a subset of XeC-treated microvessels. XeCpretreatment blunted the thrombin-induced increase in CF488A-phalloidin fluorescence
(Figure 3-5A, B). The blunting was evident in all microvessels within the XeC-treated
region (Figure 3-5C). Thus, the data indicate that IP3-dependent ER store Ca2+ release
mediated the thrombin-induced microvessel F-actin formation in both the thrombintreated and -free regions.
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Figure 3-4. Effect of endothelial Cx43 on F-actin formation
Thrombin (5 U/ml) or PBS was instilled into microvessels in a focal region of lungs from
EC-Cx43-/- mice. (A) Confocal image composite shows CF488A-phalloidin fluorescence
following PBS instillation. (B) Montage of confocal images show CF488A-phalloidin
fluorescence following thrombin instillation. Arrowheads - site of PBS or thrombin
instillation. Dashed line - outer boundary of thrombin-treated region. Bars - 100 μm. (C)
Bar graph shows CF488A-phalloidin fluorescence normalized to baseline levels in
microvessels within and outside (at indicated distances away) the thrombin-instilled
region. Data from microvessels of Cx43fl/fl mice shown for comparison (white bars). #
sites –number of measurement sites included in analysis. n = 4 lungs per treatment group.
* = p < 0.05, *** = p < 0.001, compared to data from thrombin-instilled microvessels of
Cx43fl/fl mice.
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Figure 3-5. Effect of IP3R inhibition on F-actin formation
ER IP3R inhibitor, XeC (25 μM) or Ringer’s was infused into lung microvessels of
Cx43fl/fl mice followed by instillation of PBS or thrombin (5 U/ml) into a small subset of
XeC-treated microvessels. (A) Confocal image composite shows CF488A-phalloidin
fluorescence in Ringer’s pretreated and PBS-instilled microvessels. (B) Montage of
confocal images show CF488A-phalloidin fluorescence in XeC pretreated and thrombininstilled microvessels. Arrowheads - site of instillation. Dashed line - outer boundary of
thrombin-treated region. Bars - 100 μm. (C) Bar graph shows CF488A-phalloidin
fluorescence normalized to baseline levels in microvessels within and outside (at
indicated distances away) the thrombin-instilled region. Black and white bars show data
from XeC- and Ringer’s-pretreated microvessels, respectively. # sites –number of
measurement sites included in analysis. n = 4 lungs per treatment group. ** = p < 0.01,
*** = p < 0.001, compared to data from Ringer’s-pretreated thrombin-instilled
microvessels.
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IP3 Mediates the Spatially Extensive Actin Stress Fiber Formation
Gap junctions facilitate the intercellular transfer of both Ca2+ and IP3 [89, 90].
Thus, interendothelial diffusion of either IP3 or Ca2+ from the thrombin-treated
microvessels could have caused the increase in F-actin in microvessels located outside
the thrombin-treated region. Hence to define the specific second messenger involved, we
instilled XeC into microvessels in a small lung region of Cx43fl/fl mice, followed by
instillation of thrombin into an adjacent region that overlapped the XeC-treatment region
(Figure 3-6B). Labeling microvessels with CF488A-phalloidin revealed that the
fluorescence was low in the XeC-instilled microvessels, but high everywhere else.
Quantifying the response revealed that CF488A-phalloidin fluorescence remained at
baseline levels only in the XeC-treated microvessels (Figure 3-6C). Thus, the data
clearly indicate that thrombin-induced increase in F-actin was evident in the XeC-free,
but absent in the XeC-treated regions. In contrast, when XeC was replaced with PBS, the
thrombin-induced increase in CF488A fluorescence was evident in all microvessels,
including those instilled with PBS (Figure 3-6A, C). These data suggest that the
thrombin-induced response was blunted only in microvessels pretreated with XeC.
Together the results suggest that IP3, but not Ca2+, was the second messenger mediating
the thrombin-induced spatially extensive responses in microvessels.
Thrombin Increases the Magnitude of ER-Dependent Ca2+ Oscillation in Lung
Microvessels
In endothelial monolayers, thrombin induces IP3-dependent release of ER store
Ca2+, which increases mean endothelial cytosolic Ca2+ [112-114]. However, the
characteristic of the thrombin-induced Ca2+ response in lung microvessels is not clear.
Emerging discussion suggests differences in signaling between lung microvessels and
lung microvascular endothelial cells in culture [84]. Thus, we hypothesized that Ca2+
responses to thrombin in microvessels may differ from that reported in endothelial
monolayers. To test this, we infused thrombin into microvessels of isolated bloodperfused rat lungs loaded with Fura2 AM. Changes in the ratio of Fura2 fluorescence at
340 and 380 nm excitation indicated that thrombin infusion increased Ca2+ levels in lung
microvessels (Figure 3-7A-D). Quantifying the Ca2+ response over the duration of the
experiment, as reported [103], indicated that thrombin increased the magnitude of
cytosolic Ca2+ oscillations in lung microvessels (Figure 3-7F). Infusing thrombin into the
same microvessels for a second time duplicated the Ca2+ response (Figure 3-7F).
To determine the Ca2+ source, the experiments were repeated after treating
microvessels with XeC. XeC pretreatment blunted the thrombin-induced increase in
oscillation amplitude (Figure 3-7E, G). Quantifying the amplitude of Ca2+ oscillations
indicated a concentration-dependent response to thrombin (Figure 3-7H). XeC and
tBHQ, an inhibitor of ER Ca2+-ATPase pumps [117], both blunted the increase in Ca2+
oscillation amplitude (Figure 3-7I). Together, the data suggest that thrombin increases
IP3-mediated ER Ca2+ release leading to increases in the magnitude of cytosolic Ca2+
oscillations in lung microvessels.
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Figure 3-6. Effect of focal IP3R inhibition in lung microvessels of Cx43fl/fl mice
(A) Montage of confocal images show CF488A-phalloidin fluorescence in microvessels
following separate intravascular instillation of thrombin (5 U/ml; white outline) and PBS
(yellow outline) into overlapping regions. Bar - 100 μm. (B) Montage of confocal images
showing CF488A-phalloidin fluorescence in microvessels following separate
intravascular instillation of thrombin (5 U/ml; white outline) and XeC (25 μM; red
outline) into overlapping regions. Bar - 100 μm. (C) Bar graph compares CF488Aphalloidin fluorescence in single microvessels located in the various regions as indicated.
PBS in - within PBS-instillation region; XeC in - within XeC-instillation region; PBS out
- outside PBS- and thrombin-instillation regions; XeC out - outside XeC- and thrombininstillation regions. Average fluorescence of microvessels within the thrombin-instilled
region was used to normalize the fluorescence data of other regions. * = p < 0.05, *** = p
< 0.001 compared to XeC in, respectively. # sites –number of measurement sites included
in analysis. n = 4 lungs per treatment group.
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Figure 3-7. Thrombin-induced Ca2+ responses in lung microvessels
(A-E) Pseudocolored images show fluorescence due to excitation at 340 and 380 nm in
Fura2 AM loaded rat lung microvessels (A-B), the ratio of the fluorescence at 340 and
380 at baseline (C), during thrombin (10U/ml) infusion (D) and during thrombin (10
U/ml) infusion after pretreatment with XeC (25 μM) (E). Bar - 10 μm. (F) Tracings show
temporal changes in the Fura2 AM fluorescence ratio (F340/F380) in response to a dual
infusion of thrombin (10U/ml) into lung microvessels. Each thrombin infusion was
preceded by a Ringer’s infusion to determine baseline F340/F380 values. t10 – thrombin
(10 U/ml), hbs – Ringer’s. (G) Tracings show temporal changes in F340/F380 in
response to an infusion into microvessels of thrombin (10 U/ml) followed by XeC (25
μM) pretreatment and then another thrombin (10 U/ml) infusion. t10 – thrombin (10
U/ml), hbs – Ringer’s, xec - XeC. (H) Bar graph shows the amplitude of Ca2+ oscillations
in lung microvessels in response to infusions of 5 and 10 U/ml of thrombin. t-5 –
thrombin (5 U/ml), t-10 – thrombin (10 U/ml). †† = p < 0.01 compared to baseline; ‡‡ =
p < 0.01 compared to 5 U thrombin treatment. n = 4 lungs per treatment group. (I) Bar
graph shows the % change in amplitude of Ca2+ oscillations in lung microvessels in
response to the indicated treatments. * = p < 0.05 compared to thrombin alone treatment
at the respective concentration. n=4 lungs per treatment group.
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The present data that thrombin increases the amplitude of Ca2+ oscillations in
microvessels contrasts with reported data showing increase in mean Ca2+ concentration in
endothelial monolayers [118]. Hence to exclude the possibility that the absence of a mean
Ca2+ increase in the present study was an artifact of the imaging system, we co-loaded rat
lung microvessels with the Ca2+ cage, NP-EGTA and the Ca2+ indicator, Fluo 8, as
reported [90]. A brief exposure to a 355 nm UV beam increased mean endothelial
cytosolic Ca2+ above baseline (Figure 3-8A-C) both at the site of uncaging and adjoining
microvessels. The uncaging-induced Ca2+ increase suggests that the imaging system
captured increases in mean cytosolic Ca2+. Thus, we interpret that the predominant
response to thrombin in microvessels was an increase in cytosolic Ca2+ oscillation
magnitude.
Focal Release of Caged-IP3 Induces Cx43-Dependent Ca2+ Responses in Adjacent
Microvessels
In the lung microvascular network, Cx43-dependent mechanisms mediated the
spread of Ca2+ in response to release of Ca2+ at a focal site [90]. Hence, to determine
whether IP3 released focally will also spread similarly, we co-loaded NPE-IP3 and Fluo4
into rat lung microvessels, and then exposed the microvessels to the 355 nm UV beam.
UV uncaging caused a progressive increase in Fluo4 fluorescence at both the uncaging
site and in adjoining microvessels (Figure 3-9A). Thus, IP3 release at a focal site,
increased Ca2+ in microvessels spatially away from the uncaging site. At longer time
periods post-uncaging, the Ca2+ response declined to baseline levels. Further, the increase
in Ca2+ was highest at the site of uncaging and progressively declined at sites further
away from the uncaging site (Figure 3-9B). To determine the role of Cx43 in the
induction of responses in the spatially remote microvessels, we pretreated microvessels
with the Cx43-gap junction inhibitor, Gap27 [81] and then uncaged IP3. Gap27
completely blocked the Fluo4 fluorescence increase in microvessels located outside the
uncaging region, but not within it (Figure 3-9A, C). Thus, release of IP3 at focal sites by
uncaging, spreads to adjacent microvessels and initiated responses in a Cx43-dependent
manner.
Thrombin Mediates Spatially Extensive Increases in Microvessel Permeability
Since thrombin instillation increased F-actin in microvessels outside the
thrombin-treated region, we determined whether fluid permeability was also altered in
these microvessels. Toward this, thrombin was instilled into microvessels in a focal
region of rat lungs followed by FDx20 infusion into both the thrombin-treated and
thrombin-free neighboring regions. Images indicated that the residual fluorescence of
FDx20 was higher in both the thrombin-treated and –free microvessels compared to
Ringer’s-treated microvessels (Figure 3-10A-D). However infusion of Gap27 prior to
thrombin instillation restricted the high residual fluorescence to microvessels directly
treated with thrombin (Figure 3-10E, F). Quantifying the normalized fluorescence
revealed that thrombin increased permeability in microvessels located several hundred
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Figure 3-8. Ca2+ uncaging in lung microvessels
(A,B) Pseudocolored images show the Fluo 8 fluorescence in rat lung microvessels coloaded with NP-EGTA (75 μM) and Fluo 8 before (A) and after (B) UV uncaging of NPEGTA. Circle – site of uncaging. Bar - 10 μm (C) Bar graph shows spatial changes in
Fluo8 fluorescence in response to uncaging NP-EGTA. * = p < 0.05 compared to 0 μm. n
= 4 lungs.
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Figure 3-9. IP3 uncaging in lung microvessels
(A) Pseudocolored images show response to uncaging NPE-IP3 in rat lung microvessels
co-loaded with NPE-IP3 (2.5 μM) and Fluo4. NPE-IP3 was loaded into microvessels
using Chariot, as detailed in Methods. Images show control response in the absence of the
Cx43 gap junction inhibitor, Gap27 (top row), during infusion of Gap27 (middle), and
after wash-off of the Ga27 (bottom). Circle – site of uncaging. Bar - 20 μm. (B) Bar
graph shows NPE-IP3 uncaging-induced changes in Fluo4 fluorescence at increasing
distance from the uncaging site. ‡p < 0.05 compared to 0 μm. n = 3 lungs. (C) Bar graph
shows comparison of the spatial decay of Fluo4 fluorescence in response to IP3 uncaging
in the presence of Gap27 and after washout of Gap27. (B,C) * = p < 0.05 compared to 0
μm. n = 3 lungs.
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Figure 3-10. Effect of inhibiting intercellular communication on microvessel
permeability
PBS or thrombin (5 U/ml; 10 min) was instilled into microvessels in a focal region of a
rat lung. Subsequently, FDx20 was infused into microvessels followed by a Ringer’s
wash, as detailed in Methods. (A, B) Images show peak (A) and post-wash (B) FDx20
fluorescence in PBS-treated microvessels. Dashed line - outer boundary of microvessels
instilled with PBS. Bar - 100 μm. (C, D) Images show peak (A) and post-wash (B)
FDx20 fluorescence in thrombin-treated microvessels. Dashed line - outer boundary of
microvessels instilled with thrombin. Bar - 100 μm. (E, F) Gap27 was infused into
microvessels in a small region of a rat lung for 45 min. followed by instillation of
thrombin into subset of the Gap27-treated vessels. FDx20 was then infused into the
Gap27-treated vessels followed by a Ringer’s wash. Images show peak (E) and post-wash
(F) FDx20 fluorescence in microvessels. Dashed line - outer boundary of microvessels
instilled with thrombin. Bar - 100 μm. (G) Graph shows normalized fluorescence in
single microvessels both within (0 μm) and outside the treatment regions at distances as
indicated. *** = p < 0.001 compared to Ringer’s treatment at same indicated distance. †
= p < 0.05, ††† = p < 0.001 compared to Gap27+thrombin at same indicated distance.
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microns away from the outer edge of the thrombin-treated region (Figure 3-10G). The
spatially extensive increase was blunted in Gap27-treated microvessels. Together the data
suggested that thrombin causes Cx43-dependent hyperpermeability in lung microvessels.
Discussion
In this study, we show for the first time that the receptor-mediated agonist
thrombin initiates spatially extensive responses in microvessels via interendothelial
diffusion of IP3. Moreover, the experiments reveal that the diffusion is facilitated by
Cx43 gap junctions. Together the present data reveal a novel relationship wherein Cx43
and IP3 act in tandem to expand the ambit of thrombin-induced responses in lung
microvessels. Finally, the data suggests that signaling resulting from compartmental
increases in second messengers elicited by activation of plasma membrane receptors
differs from that generated by global cell-wide increases in second messengers elicited by
photolytic uncaging.
Utilizing focal instillations of thrombin into lung microvessels, we provide the
first evidence that IP3 increases F-actin in thrombin-treated and –free microvessels. The
present finding that IP3 increases F-actin in microvessels directly treated with thrombin is
in agreement with the reported data on thrombin-mediated responses in endothelial
monolayers [108, 119-122]. However, the finding that IP3 increases F-actin in
microvessels located in adjacent thrombin-free regions is hereto unknown.
In addition to IP3, thrombin also increases Ca2+, cAMP and ATP levels in
endothelial monolayers [92, 123, 124]. Thus, any of these diffusible second messengers
could have mediated the cytosolic Ca2+ response in the spatially remote thrombin-free
microvessels. ATP is released by endothelial cells via pannexins and connexinhemichannels on the luminal membrane, and acts on purinergic receptors of adjacent
cells [92, 125]. The luminal ATP release suggests that its actions would be evident in
endothelial cells downstream from the stimulus site. In the present study, the responses in
the thrombin-free regions were independent of blood-flow direction, thus excluding ATP
as the diffusing messenger. Thrombin induces a temporally delayed increase in cAMP
[124, 126], which signals through non-ER pathways. ER inhibition blocked the spatially
remote responses, thus, excluding cAMP as the diffusing messenger. XeC blocked IP3
receptors and thus, Ca2+ release, thereby preventing the establishment of either IP3 or
Ca2+ as the diffusible second messenger using global XeC treatment. Separate
instillations of XeC and thrombin into focal, yet intersecting regions, solved this
conundrum. In the thrombin-instilled region, neither IP3 nor ER Ca2+ release was
blocked. Hence, both second messengers were free to diffuse interendothelially into the
thrombin-free microvessels, including microvessels in the XeC-instilled region. If Ca2+
had been the diffusible second messenger, then increased F-actin would have been
evident even in the XeC-treated region. However, no increase in F-actin was evident in
microvessels in the XeC-treated region. This lack of a response only in the XeC-treated
region implicated IP3 as the diffusible messenger mediating the spatially extensive
responses from the thrombin-treated to the thrombin-free microvessels.
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The present experiments show that in lung microvessels, thrombin increased the
amplitude of endothelial cytosolic Ca2+ oscillations via ER Ca2+ release. In endothelial
monolayers, thrombin also induces ER Ca2+ release [110, 113, 114, 119]. However, the
ER Ca2+ release increases the mean endothelial cytosolic Ca2+ concentration. Thus, the
present data in microvessels stand in contrast to that from endothelial cells. The
difference in Ca2+ response could point to differences in signaling between endothelial
cells in situ and in culture. We previously noted that LPS-induced Ca2+ responses in
microvessels were different from those in endothelial monolayers [103]. Moreover, it has
recently been highlighted that thrombin activates different signaling pathways in these
two experimental models [84]. Further, the thrombin-induced Ca2+ responses may be
concentration dependent. Thus, the present data suggest that thrombin mediated
responses are dependent on the experimental model used and hence, should be viewed
from that context.
The current finding that IP3 is the diffusible messenger mediating thrombininduced responses among endothelial cells suggests that IP3-dependent Ca2+ release
mediates the F-actin increases in both thrombin-treated and –free cells. IP3-dependent ER
store Ca2+ release concomitantly increases activation of p38 mitogen-activated protein
kinase (p38-MAPK) [127-130]. However, the relationship between store Ca2+ release and
p38-MAPK activation is cell-type- and agonist-dependent. In endothelial cells, LPS
increases activation of p38-MAPK[131]. We reported that LPS causes store Ca2+ release
in lung microvessels [103]. Thus, it is possible that the thrombin-induced store Ca2+
release activated p38-MAPK. Activated p38-MAPK phosphorylates the actin-binding
protein, heat-shock protein 27 (HSP27) in endothelial and other cells via MAP kinaseactivated protein kinase 2 (MAPKAP kinase 2) [130-134]. Phosphorylation of HSP27
facilitates F-actin polymerization and stress fiber formation [135-137]. Thus, activated
p38-MAPK could increase F-actin levels via phosphorylation of HSP27 in endothelial
cells. However, this pathway requires further delineation in lung microvessels. Moreover,
other factors such as RhoA have been implicated in actin dynamics [138] and may
modulate F-actin levels either separately or in tandem with the p38-MAPK pathway.
Thus, the specific pathway and associated proteins involved in store Ca2+ releasedependent F-actin increase in lung microvessels require further consideration.
Endothelial connexins play a role in the induction of P-selectin, endothelial
permeability, and hypoxic arteriolar vasoconstriction in spatially remote microvessels
[90, 94, 139]. While both Cx43 and Cx40 have been shown to mediate the above
responses, the knockout mice experiments exclude a role for Cx40 in the present study.
The photolytic uncaging experiments add further support for Cx43 as mediating the
interendothelial diffusion of IP3 in the lung microvascular network. Cx43 supports the
diffusion of IP3 in astrocytes [88] and endothelial monolayers [89]. The present
observations concur with these previous reports. Thus, Cx43 is the predominant connexin
mediating thrombin-induced responses in microvessels.
In Cx43fl/fl mice, F-actin increased in microvessels in direct contact with
thrombin. However, the increase was smaller in microvessels of EC-Cx43-/- mice. This
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difference is intriguing because the microvessels in both mouse types were exposed to the
same concentration of thrombin and for the same duration. Thus, it is likely that Cx43
also contributed to signaling differences in thrombin-treated microvessels. Studies by
Bhattacharya’s group and others have suggested that in lung microvessels, proinflammatory responses are heterogeneous among endothelial cells [139-141]. Thus,
some endothelial cells termed pacemakers may initiate the responses that then propagate
to neighboring cells via interendothelial communication [139, 142]. Based on this, we
propose that thrombin-induced-IP3 release and downstream signaling may be
heterogeneous in lung microvessels. The heterogeneity may be attributed to endothelial
differences in thrombin receptor density or other factors involved in the signaling.
Indeed, heterogeneity in the distribution of thrombin receptors among microvessels has
been reported [143]. Thus, those endothelial cells with a higher receptor density may act
as pacemakers. The higher levels of IP3 generated by the pacemaker could diffuse to
adjacent endothelial cells along the microvessel and increase the overall response in the
entire vessel. In the absence of interendothelial communication, this transfer of IP3 may
be blocked and thus the overall microvessel response to thrombin may be mitigated.
However, the establishment of this or other possible mechanisms as the specific factors
responsible for reduction in thrombin-induced endothelial response in EC-Cx43-/- mice
requires further elucidation.
In addition to the smaller thrombin-induced increases, the baseline F-actin
fluorescence was in itself lower in EC-Cx43-/- mice. This difference could be due to
interaction of Cx43 with the actin cytoskeleton. Cx43 interaction with the actin
cytoskeleton is reported in several cell types, including brain endothelium, astrocytes and
B-cells [144-148]. Thus, it is possible that reduction in Cx43 expression lowers Cx43-Factin interaction, likely through modifying the interactions among proteins in the Cx43
interactome. For example, reduction in Cx43-ZO1 interaction reduced F-actin levels in
brain endothelial cells [144]. Accordingly, it is possible that in the EC-Cx43-/- mice, the
lack of Cx43 may have resulted in the loss of interaction among proteins in the Cx43
interactome, and thus resulted in the reduced F-actin levels. The specific proteins
involved in this interaction and the signaling involved behind the reduction in F-actin
levels will require further elucidation.
The current study indicates that activation of plasma membrane receptors induces
IP3-mediated spatial expansion of pro-inflammatory responses. In contrast, increase in
cell-wide Ca2+ by photolytic uncaging of Ca2+ induces Ca2+-diffusion-mediated spatial
expansion of responses [90]. Thus, signal compartmentalization associated with
activation of plasma membrane receptors likely defines the specific second messenger
that diffuses through the gap junctions. Since thrombin activates G protein-coupled
receptors [50], IP3 is generated closer to the plasma membrane, and thus in proximity to
gap junctions. This proximity likely facilities IP3 diffusion through the gap junctions.
This argument is further supported by the smaller spatial spread of the response
associated with IP3 uncaging. As uncaging increased IP3 in a cell-wide manner, relatively
low levels of IP3 would be available at the cell-cell junction and thus for diffusion via gap
junctions. This would limit the ambit of responses to IP3 uncaging, but not for receptormediated IP3 increase. While IP3 also triggers ER store Ca2+ release, the inherent
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compartmentalization of Ca2+ due to the steep decline in its concentration from the
release site [149] may also limit its availability in the vicinity of gap junctions. In
addition, in the present study, the cellular Ca2+ response was an increase in the magnitude
of cytosolic Ca2+ oscillations, rather than an increase in mean cytosolic Ca2+
concentration. This difference in Ca2+ response may underlie the preclusion of Ca2+
diffusion via gap junctions, and needs explored further. Whether these interpretations of
spatial compartmentalization is applicable to other pro-inflammatory mediators that
induce interendothelial signaling also remains to be elucidated.
In conclusion, our studies here showed that IP3 generated in response to thrombin
is the specific second messenger mediating the thrombin-induced responses of increased
F-actin formation and permeability in the pulmonary microvasculature, and that the
interendothelial communication of IP3 via Cx43 mediates the spatial expansion of these
responses. Our experiments also demonstrated that the origin of the second messenger, as
determined by the stimulus, defines both the breadth and the type of response observed.
Our work here highlights the differences between inflammatory signaling observed in
culture and in in situ. Further investigations utilizing more physiologically-relevant in
situ preparations may reveal strategies that limit these expansive inflammatory responses
through the targeted blocking of interendothelial communication.
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CHAPTER 4.

COOPERATIVE SIGNALING OF THROMBIN AND S1P2 IN
BARRIER DYSFUNCTION
Introduction

S1P is a lysophospholipid signaling molecule that acts through G-protein coupled
receptors on endothelial cells to mediate various cellular activities, including
microvascular permeability [9, 62, 67]. While signaling through the primary receptor
S1P1 is barrier-protective, signaling through S1P2 has been found to be barrier-disruptive
[4, 68, 69]. The expression of both S1P and the receptor S1P2 has been shown to be
increased in inflammation [62, 65, 70]. In HMVEC monolayers, inflammatory mediators
LPS and TNFα were shown to induce increases in both S1P2 mRNA and protein, and
blocking S1P2 signaling in these cells blocked the LPS- and TNFα-induced increases in
barrier permeability [70]. In addition, in isolated perfused rat lungs, it was found that
blocking S1P2 signaling also blocked in the induction of lung edema and increased
permeability by hydrogen peroxide [69] While S1P2 signaling displays a clear link to
hyperpermeability in the context of inflammatory mediators, little has been shown on
direct effects in lung microvessels.
The inflammatory mediator thrombin activates the receptor PAR-1, and activation
of PAR-1 has been shown to activate SphK1 and induce local increases in S1P [62, 63,
67]. In fact, in endothelial monolayers, it has been indicated that this increase may
mediate the thrombin-induced hyperpermeability [150]. In addition, the inhibition of
SphK1 in endothelial cells also inhibits the thrombin-induced increases in cytokine
production and secretion [63]. Both PAR-1 and S1P2 activation is mediated by the Gproteins Gαi, Gαq, and Gα12/13, leading to calcium store release, RhoA activation, and
subsequent increases in permeability [61, 69, 98, 151-154]. While the dual activation of
these receptors may lead to a cooperative effort in inflammation, it is unknown the extent
to which S1P2 signaling may actually participate in or contribute to thrombin-induced
signaling within lung microvessels. Further, though other inflammatory mediators may
affect S1P2 expression, it is unknown whether thrombin may have a similar effect,
specifically within pulmonary microvascular endothelium.
To explore the possible role of S1P2-directed signaling in lung inflammation, we
studied changes in S1P2 expression in pulmonary microvascular endothelial cells and
microvessels induced by the inflammatory mediator thrombin in addition to exploring
S1P2 signaling in the context of thrombin-induced endothelial hyperpermeability. As the
gap junction channel protein Cx43 has been shown to mediate thrombin-induced spatially
extensive responses, we investigated thrombin-induced changes in S1P2 in both our
Cx43fl/fl and EC-Cx43-/- mouse lines [155]. Our results show that thrombin is able to
induce an increase in S1P2 expression in primary mouse pulmonary microvascular
endothelial cells (PMVECs) as well as pulmonary microvessels in Cx43fl/fl and EC-Cx43/mouse lungs. Interestingly, while the increase in expression was nominal and confined
to the thrombin-treated area in our EC-Cx43-/- mouse line, in the Cx43fl/fl mouse lungs
thrombin induced a significant increase in the treated area and an even greater increase
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outside of the treated microvessels. To further investigate this unique pattern of
thrombin-induced effects, we also looked at ROS generation following thrombin
treatment. Similar to S1P2 expression, we found that thrombin induced a greater increase
in ROS outside of the treatment area than inside in the Cx43fl/fl mouse lungs. Finally, to
study contributions of S1P2 signaling in thrombin-induced increases in microvascular
permeability, we pretreated microvessels with the S1P2 antagonist JTE-013. We found
that blocking S1P2 signaling effectively blocked thrombin-induced increases in ROS
generation as well as hyperpermeability. Our results show that in pro-inflammatory
signaling, thrombin may induce increased presence of S1P2 in pulmonary microvascular
endothelial cells in a manner mediated by gap junctional communication, and signaling
following S1P2 activation contributes to thrombin-induced effects in the
microvasculature.
Materials and Methods
Animals
All mouse studies were approved by the Institutional Animal Care and Use
Committee of the University of Tennessee Health Science Center. Endothelial specificCx43 knockout (EC-Cx43-/-) mice on a C57BL/6J background were bred in our animal
facility as previously reported [90, 100, 155], and age-matched floxed Cx43 (Cx43fl/fl)
mice were used as controls. Mice were given access to food and water ad libitum, and
placed on a 12 h light-dark cycle.
Fluorophores and Reagents
Thrombin (10 U/mL), sphingosine-1-phosphate (S1P; 10 μM), fluorescein
isothiocynate 20 kDa (FDx20; 0.5 mg/mL), rhodamine-dextran 70 kDa (RDx70; 0.5
mg/mL), and N-acetyl cysteine (NAC; 5 μM) were from SigmaAldrich (St. Louis, MO).
The nuclear marker Hoeschst-33342 (10 μg/mL) was from Teflabs (Austin, TX). The cell
permeable dye Calcein AM (1.25 μM) was from Invitrogen (Carlsbad, CA). The S1P2
receptor antagonist JTE-013 (1 μM) was from Cayman Chemical. Collagenase Type II
(10 mg/mL) was obtained from Worthington Biochemical (Lakewood, NJ). The
fluorescent reactive oxygen species indicator CellROX deep red reagent (15 μM) was
from ThermoFisher (Waltham, MA). The anti-S1P2 Antibody (5-10 μg/mL) came from
MilliporeSigma (Billerica, MA). The CF488A-conjugated goat anti-mouse secondary
antibody (1 μL/mL) was from Biotium (Hayward, California). Fluorophores and reagents
were infused into pulmonary microvessels in a Ca2+-rich HEPES-buffered Ringer’s
solution (HBS; 150 mM Na+, 5 mM K+, 1 mM Ca2+, 1 mM Mg2+, 10 mM glucose, 20
mM HEPES) with 4% dextran (40 kDa) and 1% fetal bovine serum at a final pH of 7.4.
Phosphate buffered saline with Ca2+ and Mg2+ (PBS) was from GE Life Sciences
(Pittsburg, PA).
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Lung Preparation
Isolated perfused lungs were prepared from mice as reported [155]. Adult mice
were anesthetized by intraperitoneal injection of ketamine and xylazine, exsanguinated
via cardiac puncture, and the blood was collected in heparin. The chest cavity was
opened, and cannulae were placed in the trachea, pulmonary artery, and left atrium. The
lungs and heart were excised en bloc, and moved to the microscope stage. Through the
tracheal cannula the lungs were constantly inflated with room air at a pressure of 5 cm
H2O. The lungs were constantly pump-perfused at a rate of 2 mL/min, and pressures in
the pulmonary artery cannula and left atrial cannula were maintained at 10 and 3 cm H2O,
respectively.
S1P2 Expression in PMVECs
Mouse lung microvascular endothelial cells were isolated from Cx43fl/fl and ECCx43 lungs by collagenase II digestion and cultured overnight at 37°C in medium 199
supplemented with growth factors on fibronectin-coated coverslips. The following day,
coverslips were treated with thrombin (10U/mL) for 10 minutes (or no treatment in the
case of control). The coverslips were washed three times with PBS and then fixed for 10
minutes with 3.7% paraformaldehyde. The cells were then again washed thrice with PBS
and then permeabilized with 0.05% Triton X for 10 minutes. They were washed 3 more
times with PBS and then blocked using 5% bovine serum albumin for 1 hour. The cells
were then incubated overnight at 4°C with anti-S1P2 monoclonal Ab (5 μg/mL). The
next morning, the cells were again washed 3 times with PBS then incubated for 1 hour
with CF488A-conjugated secondary antibody (1 μL/mL) and a nuclear stain (Hoeschst33342, 10 μg/mL). After washing again with PBS, the coverslips were imaged using a
confocal microscope (LSM710; Carl Zeiss Inc., Thornwood, NY). To quantify secondary
antibody fluorescence, an outline was drawn at the perimeter of endothelial cells and a
measurement of the average fluorescence was taken from several cells in each image.
-/-

S1P2 Expression in Pulmonary Microvessels
In IPLs from Cx43fl/fl and EC-Cx43-/- mice, a PE10 microcatheter was inserted
through the left atrium and used to infuse HBS to clear a small section of the
microvasculature of blood. Near a targeted post-capillary venule, an alveoli was
micropunctured and filled with 2% Sudan black in oil to be used as a marker. A venule
was then micropunctured and an instillation mixture of either Thrombin (10 U/mL) or
PBS with RDx70 (.5 mg/mL) was given over 10 minutes. The RDx70 fluorescence was
used to confirm instillation into the vasculature and to delineate treated microvessels.
Microvessels in the cleared area were then fixed and permeabilized via catheter, with 30
minute infusions of 3.7% paraformaldehyde and 0.05% Triton X, respectively. Following
a 30 minute blocking infusion of 5% bovine serum albumin, successive infusions of S1P2
primary Ab in HBS for 30 minutes, HBS alone for 20 minutes, and finally CF488Aconjugated secondary Ab for 30 minutes were given to fluorescently tag the S1P2 protein
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in the pulmonary microvasculature. Hoeschst-33342 was infused with the secondary
antibody to stain the nuclei. Following staining, confocal images were obtained both in
the area of micropuncture instillation as well as outside (600+ μm away from treated
microvessels). The nuclear stain was used to define vessel location in images with low
CF488A-conjugated secondary Ab fluorescence. Secondary antibody fluorescence was
measured at random sites along the microvasculature both within and outside of the
treated vessels, and several vessels were measured in each image.
Thrombin-induced ROS Generation
In isolated perfuse lungs from Cx43fl/fl and EC-Cx43-/- mice, a PE10 microcatheter
was used to clear an area of the vasculature and to give a 30 minute infusion of CellROX
deep red reagent and Calcein AM. Following a 30 minute equilibration period during an
HBS infusion, confocal images were taken of two separate venules 600+ μm apart. One
of the imaged venules was then micropunctured with either Thrombin (10 U/mL) or PBS
with RDx70 (.5 mg/mL) instilled over 10 minutes. The two previously targeted venules
were then imaged again. CellROX and Calcein AM fluorescence was measured at
random sites along the microvasculature in both areas, before and immediately after the
micropuncture instillation. The change in the ratio of CellROX/Calcein AM fluorescence
was used to determine induction of ROS generation. As this is a live-cell process, and
CellROX fluorescence may decrease naturally even though ROS amounts continue to
increase (by prolonged, continued oxidation of the dye), the Calcein AM fluorescence
was used as a guide to ensure that increases or decreases in ROS generation were
adequately determined.
In experiments to investigate S1P/S1P2-induced changes in ROS generation, a
PE10 microcatheter was used to clear a section of the vasculature of Cx43fl/fl mouse
lungs and CellROX and Calcein AM were infused for 30 min. Following the
equilibration period, confocal z-stack images were taken of approximately 4 different
areas surrounding a venule. Next, an infusion of either Thrombin (10 U/mL; 10 minutes)
or S1P (10 μM; 20 minutes) was given via the microcatheter, with or without a 15 minute
pretreatment infusion of JTE-013 (1 μL/mL). After treating the microvasculature, z-stack
images were taken again of the same venular areas and changes in ROS were determined
as described above.
Microvascular Permeability
In isolated perfused Cx43fl/fl mouse lungs, a PE10 microcatheter was used to clear
an area of microvessels. Following treatment of Thrombin (10 U/mL; 10 minutes) or S1P
(10 μM; 20 minutes), an infusion of FDx20 (.5 mg/mL) was given over 1 hour. At least
20 minutes prior to the end of the FDx20 infusion, imaging was started, taking 1 image of
the FDx20 fluorescence every minute, centered at a single microvessel. At the end of the
FDx20 infusion, an infusion of HBS was started and continued for a minimum of 30
minutes, with imaging continuing at the same rate. FDx20 fluorescence was measured at

44

random sites along the vasculature for the duration of the image series. Permeability was
determined by normalizing the peak FDx20 fluorescence to 1000 AU and calculating the
average decrease in intensity over the first 10 minutes following the peak. In experiments
in which S1P2 signaling was inhibited, JTE-013 (1 μL/mL) was infused for 15 minutes
prior to treatment. In experiments were ROS generation was inhibited, NAC (5 μM) was
given for 1 hour prior to treatment. In experiments where thrombin and S1P were given at
the same time, first S1P was infused for 10 minutes and then both S1P and thrombin were
infused for an additional 10 minutes.
Statistics
All data reported as mean ± SEM. All groups were compared with Kruskal-Wallis
one-way ANOVA on Ranks, followed by pairwise multiple comparisons by Dunn’s
method.
Results
Thrombin Induces Differing Effects on S1P2 Expression in Both PMVECs and
Microvessels in Cx43fl/fl and EC-Cx43-/- Mice
S1P2 expression in PMVECs isolated from Cx43fl/fl and EC-Cx43-/- mouse
lungs following thrombin treatment. While different inflammatory mediators have
been shown to induce an increase in S1P2 expression in endothelial cells [70], this effect
has not been studied in relation to thrombin. We first established expression of the S1P2
receptor in primary PMVECs at baseline and following thrombin treatment. Briefly, from
both Cx43fl/fl and EC-Cx43-/-mice, we removed the lungs, isolated the microvascular
endothelial cells, and allowed them to adhere and grow on coverslips overnight. The cells
were then fixed, permeabilized, and S1P2 expression was determined using
immunofluorescence (Figure 4-1A). Primary endothelial cells isolated from Cx43fl/fl and
EC-Cx43-/-mouse lungs showed similar levels of baseline fluorescence, with the ECCx43-/- cells exhibiting slightly higher secondary Ab fluorescence (Cx43fl/fl baseline =
236.0 ± 17.7 gy lvls; EC-Cx43-/- baseline = 347.3 ± 27.6 gy lvls). Interestingly, EC-Cx43/cells that had been treated with thrombin prior to fixing displayed a slightly decreased
S1P2 expression compared to baseline (EC-Cx43-/- thrombin = 249.3 ± 20.1 gy lvls). The
opposite effect was observed in the Cx43fl/fl primary PMVECs in which thrombin
induced a dramatic and significant increase in S1P2 expression (Cx43fl/fl thrombin =
1099.0 ± 25.2 gy lvls)(Figure 4-1B). Overall, this shows that thrombin treatment leads to
an increase in S1P2 expression in Cx43fl/fl, but not EC-Cx43-/-, isolated PMVECs.
S1P2 expression in pulmonary microvessels. We further explored thrombininduced S1P2 expression in the pulmonary microvasculature of isolated Cx43fl/fl and ECCx43-/- mouse lungs. Similar to what was done in the isolated cells, S1P2 expression was
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Figure 4-1. S1P2 expression in mouse PMVECs
(A,B) Confocal images and graph of immunofluorescence of S1P2 in isolated PMVECs
from Cx43fl/fl (first column) and EC-Cx43-/- (second column) mice, at baseline (first row)
and after thrombin (second row, 10 U/mL) treatment. Bars = 5 μm. *** = p<.001, **** =
p<.0001 compared to Cx43fl/fl + thrombin treatment. n = 3 coverslips for all groups.
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determined by immunofluorescence. At baseline, we found that in the Cx43fl/fl lungs there
was a low level of S1P2 expression in both the venules and the capillaries (Figure 4-2A).
However, in the EC-Cx43-/- mouse lungs we saw strikingly higher levels of S1P2
expression, with immunofluorescence being approximately 5x and 15x what was seen in
the Cx43fl/fl capillaries and venules, respectively (Figure 4-2B). This result was
particularly surprising because, while EC-Cx43-/- cells displayed elevated S1P2
expression over Cx43fl/fl cells, this was modest and not significant.
We next studied S1P2 expression following local micropuncture instillations of
either thrombin or PBS (for control). Similar to what was observed in the isolated
PMVECs, thrombin treatment induced an increase in S1P2-mediated fluorescence in both
venules and capillaries (Figure 4-3A). For both, while the increase inside the actual
thrombin-treated microvessels was minor, the increase in venules and capillaries ~600μm
away from the micropunctured area was quite sizeable and significantly higher compared
to inside (Figure 4-3B and C). These results indicate that the thrombin treatment induced
an increase in the presence of S1P2 in microvessels directly treated and in neighboring,
untreated microvessels.
Conversely, thrombin induced the opposite effect in the microvessels of the ECCx43 mouse lungs (Figure 4-4A). In the venules, there was an insignificant increase
over PBS control within the treated area. In the outside venules, thrombin treatment
actually led to a significant decrease in S1P2 expression compared to both the directly
thrombin-treated venules as well as venules outside of the PBS-treated area (Figure 44B). In the capillaries, thrombin treatment induced a significant decrease in S1P2
immunofluorescence compared to PBS control both within and outside of the
micropunctured areas (Figure 4-4C). Thus, the absence of Cx43 in endothelial cells
blunts thrombin-induced S1P2 responses.
-/-

In comparing the results from Cx43fl/fl and EC-Cx43-/- lungs, while there was no
significant difference between thrombin-treated venules of the two genotypes, there were
significant differences between the outside venules as well as the inside and outside
capillaries from the Cx43fl/fl and EC-Cx43-/- mouse lungs (Figure 4-5). Therefore, while
there is significantly more S1P2 present in pulmonary microvascular endothelium of ECCx43-/- mice at baseline, thrombin treatment induces an increase in expression in both
directly-treated and faraway microvessels of the Cx43fl/fl mouse lungs as well as an
overall decrease in S1P2 expression in the EC-Cx43-/- lung microvessels.
Induction of ROS Generation by Thrombin in Pulmonary Microvessels
We next chose to explore thrombin-induced generation of ROS in microvessels
following local thrombin treatment, as ROS may be generated through PAR-1-depedent
activation of Nox2 [51, 156]. We have previously shown that thrombin is able to induce
F-actin polymerization in both thrombin-treated and –free microvessels
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Figure 4-2. Baseline S1P2 expression in mouse pulmonary microvessels
(A,B) Confocal images and graph of immunofluorescence of S1P2 in pulmonary
microvessels of Cx43fl/fl and EC-Cx43-/- mouse lungs at baseline. Bars = 100 μm. **** =
p<.0001 compared to Cx43fl/fl microvessels. n = 3 lungs for both genotypes.
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Figure 4-3. S1P2 expression in microvessels of Cx43fl/fl mouse lungs instilled with
PBS or Thrombin
(A) Confocal images of immunofluorescence of S1P2 in pulmonary microvessels of
Cx43fl/fl mouse lungs following micropuncture instillation of either PBS (first column) or
thrombin (second column,10 U/mL) treatment. Images captured in (first row) and out
(second row) of micropunctured area. Bars = 100 μm. (B,C) Graphs showing S1P2
immunofluorescence normalized to baseline levels in venules (B) and capillaries (C). ***
= p<.001, **** = p<.0001 compared to microvessels outside of thrombin-treated area. n
= 3 for PBS-treated lungs. n = 4 for thrombin-treated lungs.
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Figure 4-4. S1P2 expression in microvessels of EC-Cx43-/- mouse lungs instilled
with PBS or Thrombin
(A) Confocal images of immunofluorescence of S1P2 in pulmonary microvessels of ECCx43-/- mouse lungs following micropuncture instillation of either PBS (first column) or
thrombin (second column,10 U/mL) treatment. Images captured in (first row) and out
(second row) of micropunctured area. Bars = 100 μm. (B,C) Graphs showing S1P2
immunofluorescence normalized to baseline levels in venules (B) and capillaries (C).
(B)* = p<.05 compared to venules outside of thrombin-treated region. (C) * = p<.05, ***
= p<.001 compared to capillaries in PBS-treated lungs in indicated areas. n = 3 for both
treatment groups.
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Figure 4-5. Comparison of S1P2 expression following Thrombin treatment in
pulmonary microvessels of Cx43fl/fl and EC-Cx43-/- mouse lungs
(A,B) Bar graphs depict S1P2 immunofluorescence following thrombin treatment
normalized to baseline, untreated values in venules (A) and capillaries (B). **** =
p<.0001 compared to Cx43fl/fl microvessels in indicated areas. n = 4 Cx43fl/fl mouse
lungs, n = 3 EC-Cx43-/- mouse lungs.
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by intercellular communication through Cx43-containing gap junctions [155], and we
sought to determine if this other mediator of the thrombin permeability response may be
induced in a similar spatially extensive manner. We evaluated ROS generation as the
change in the ratio of CellROX deep red reagent (an indicator of ROS) fluorescence over
Calcein AM fluorescence, before and after a micropuncture instillation of either thrombin
or PBS. Thrombin induced significant increases in ROS within treated microvessels, with
the change in the CellROX/Calcein AM ratio being double what was seen in PBS control
for both treated venules and capillaries (Figure 4-6). Thrombin treatment also lead to
increases in the untreated microvessels, with the change in the CellROX/Calcein AM
ratio being double and triple control values for the venules and capillaries, respectively.
However, in the EC-Cx43-/-, thrombin was able to induce only modest increases
within thrombin-treated venules and capillaries that were not significant compared to
control (Figure 4-7). In the untreated venules outside of the thrombin treatment, there
was a significant decrease in the generation of ROS compared to treated venules, with
values being nearly identical to PBS instillation values. In the outside capillaries, there
was a minor increase compared to PBS instillation, but there was still less of a change in
the CellROX/Calcein AM ratio compared to capillaries within the thrombin treated
region.
Overall, there was a significantly higher increase in ROS generation following
thrombin treatment in all evaluated venules and the outside capillaries of Cx43fl/fl mouse
lungs when compared to EC-Cx43-/- pulmonary microvasculature (Figure 4-8). Thus,
thrombin induces increases in ROS generation in treated and faraway, untreated
microvessels, and the spatial expansion of this response in dependent on Cx43-containing
gap junctions.
S1P2 Signaling Contributes to Thrombin-Induced Increase in Pulmonary
Microvascular Permeability
As both PAR-1 and S1P2 signaling has been shown to be barrier-destructive and
stems from the activation of the same G-proteins, we evaluated whether or not there was
any cooperation between the two pathways in pulmonary endothelial hyperpermeability.
S1P, through its receptor S1P2, increases lung microvascular permeability.
We first established the consequences of S1P2 signaling in permeability of pulmonary
microvessels. To that end, following treatment with S1P with or without the S1P2
antagonist JTE-013, we infused FDx20 kDa via catheter for 60 minutes. We determined
the fall in fluorescence within the first 10 minutes after peak FDx20 fluorescence and
switch to HBS infusion (calculated as gray levels/min). Therefore, the higher the gy
lvls/min value, the more FDx20 kDa is washing out, the lower the permeability.
Interestingly, we found that in this microvascular bed S1P itself induced a statistically
significant increase in permeability compared to control (no treatment) and microvessels
treated with JTE-013(Figure 4-9 A,B). However, when S1P2 signaling was blocked by a
JTE-013 pretreatment, this increase was likewise blocked. We also sought to determine
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Figure 4-6. Induction of ROS generation following Thrombin micropuncture
instillation in microvessels of Cx43fl/fl mouse lungs
(A) Confocal images of CellROX deep red reagent fluorescence (first column), Calcein
AM fluorescence (second column), and merge of the two (third column) following
thrombin micropuncture instillation in Cx43fl/fl mouse lungs. Images captured inside
instillation area before (first row) and after (second row) thrombin (10 U/mL) treatment,
as well as outside micropunctured area before (third row) and after (fourth row)
treatment. Bars = 100 μm. (B,C) Bar graphs show the ratio of CellROX deep red reagent
fluorescence over Calcein AM fluorescence, normalized to values before micropuncture
instillation of either PBS or thrombin (10 U/mL), in venules (B) and capillaries (C). * =
p<.05, ** = p<.01 compared to values obtained in PBS-instilled lungs in indicated areas.
n = 3 for both treatment groups.
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Figure 4-7. Induction of ROS generation following Thrombin micropuncture
instillation in microvessels of EC-Cx43-/- mouse lungs
(A) Confocal images of CellROX deep red reagent fluorescence (first column), Calcein
AM fluorescence (second column), and merge of the two (third column) following
thrombin micropuncture instillation in EC-Cx43-/- mouse lungs. Images captured inside
instillation area before (first row) and after (second row) thrombin (10 U/mL) treatment,
as well as outside micropunctured area before (third row) and after (fourth row)
treatment. Bars = 100 μm. (B,C) Bar graphs show the ratio of CellROX deep red reagent
fluorescence over Calcein AM fluorescence, normalized to values before micropuncture
instillation of either PBS or thrombin (10 U/mL), in venules (B) and capillaries (C). * =
p<.05 compared to values obtained in venules inside thrombin-treated area. n = 3 PBStreated lungs, n = 4 thrombin-treated lungs.
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Figure 4-8. Comparison of ROS generation following Thrombin treatment in
pulmonary microvessels of Cx43fl/fl and EC-Cx43-/- mouse lungs
(A,B) Bar graphs show ratio of CellROX deep red reagent fluorescence over Calcein AM
fluorescence, normalized to values before micropuncture instillation of thrombin (10
U/mL), in venules (A) and capillaries (B). ** = p<.01, *** = p<.001, **** = p<.0001
compared to Cx43fl/fl microvessels in indicated areas. n = 3 Cx43fl/fl lungs, n = 4 ECCx43-/- lungs.
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Figure 4-9. S1P2 signaling in pulmonary microvascular permeability
(A) Pseudocolored images showing FDx20 fluorescence at peak (first column) and 5
minutes into HBS wash following peak FDx20 fluorescence (second column) in Cx43fl/fl
mouse lungs following treatment with JTE-013 (first row, 1 μM), S1P (second row, 10
μM), S1P + JTE-013 (third row), thrombin (fourth row, 10U/ml) or thrombin+JTE-013
(fifth row). Bars = 100 μm. (B,C) Bar graph shows the change in FDx20 fluorescence, as
gray levels/min, following microcatheter infusion of indicated treatments. (B)** = p<.01,
****=p<.0001 compared to thrombin alone, respectively.. $=p<.05, $$=p<.01 compared
to S1P alone, respectively. n = 4 for control, S1P-, S1P+JTE-013-, and thrombin-treated
lungs, n = 5 for JTE-013- and thrombin+JTE-013-treated lungs. (C) * = p<.05, ** =
p<.01 compared thrombin followed by S1P treatment. n = 4 thrombin-treated lungs, n = 3
thrombin+S1P-treated lungs, n = 3 thrombin- THEN S1P-treated lungs.
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Figure 4-9

(Continued)
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the depth to which S1P2 signaling may contribute to thrombin-induced increases in
permeability in pulmonary microvessels. As observed previously, a catheter infusion of
thrombin greatly increased endothelial barrier permeability compared to control and
treatment with JTE-013 alone (Figure 4-9 A,B). However, when JTE-013 was used to
prior to thrombin infusion, barrier integrity returned to control levels (Figure 4-9B).
These results show that, in lung microvessels, signaling originating from the S1P2
receptor leads to barrier disruption and that S1P2 signaling plays a role in thrombininduced permeability increases.
To further study this relationship, as well as the effects of increased S1P
production, we examined the consequences on permeability of giving S1P both
concurrently with thrombin as well as following thrombin treatment. We found that when
S1P is given following thrombin infusion, there is a significantly diminished impact on
permeability compared to S1P given during thrombin as well as to thrombin alone
(Figure 4-9C). This shows that S1P application, given following treatment with the
inflammatory mediator thrombin, may help to alleviate the hyperpermeability response.
Inhibition of S1P2 signaling pathways blocks thrombin-induced ROS
generation in Cx43fl/fl pulmonary microvasculature. Because we observed both that
S1P2 signaling was able to augment thrombin-induced signaling and that S1P itself can
induce an increase in permeability, we next sought to establish whether signaling through
S1P2 had any effect on thrombin-initiated ROS production. For this, we again used the
change in the ratio of CellROX fluorescence over Calcein AM fluorescence, before and
after treatment with thrombin and/or JTE-013, to determine changes in ROS content of
the microvasculature. As we observed in previous experiments, thrombin infusion
initiated a significant increase in ROS (Figure 4-10). However, when thrombin was
given following infusion of JTE-013, this increase was completely abolished. In addition,
we found that S1P treatment also lead to an increase in ROS generation that was blocked
by JTE-013 pre-treatment. Thus, S1P2 signaling is required for the thrombin- and S1Pinduced increase in ROS production in pulmonary microvessels.
Increases in permeability induced by S1P and thrombin are due to increases
in ROS generation. Finally, we sought to investigate whether the increase in ROS
generation that is being mediated by S1P2 is also responsible for the subsequent changes
to barrier integrity induced by thrombin and S1P. Towards this, the microvessels were
pretreated with NAC, an antioxidant and inhibitor of ROS generation. We found that
blocking ROS generation completely abolished increases in permeability due to thrombin
and S1P (Figure 4-11). Thus, the increased ROS generation induced by thrombin and
S1P is mediating the increased permeability caused by these two inflammatory mediators.
Discussion
This study shows for the first time that, in both isolated primary PMVECs as well
as in pulmonary microvessels from Cx43fl/fl mouse lungs, the inflammatory mediator
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Figure 4-10. S1P2 signaling in Thrombin-induced ROS generation
(A) Confocal images of CellROX deep red reagent fluorescence (first column), Calcein
AM fluorescence (second column), and merge of the two (third column) before and after
treatment of microvasculature with JTE-013 (1 μM) and/or thrombin (10 U/mL) in ECCx43-/- mouse lungs. Bars = 100 μm. (B) Bar graph shows the ratio of CellROX deep
red reagent fluorescence over Calcein AM fluorescence, normalized to values before
treatment with indicated agents. *** = p<.001 compared to thrombin treatment group.
$=p<.05, $$$=p<.001 compared to S1P treatment group. n = 3 for JTE-013-,
thrombin+JTE-013-, S1P-, and S1P+JTE-013-treated lungs. n = 4 for thrombin-treated
lungs.
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Figure 4-10

(Continued)
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Figure 4-11. Inhibition of ROS generation in S1P- and Thrombin-induced
hyperpermeability
(A) Bar graph shows the change in FDx20 fluorescence, as gray levels/min, following
microcatheter infusion of indicated treatments. ***=p<.001, ****=P<.0001 compared to
thrombin treatment group. $$=p<.01, $$$=p<.001 compared to S1P treatment group.
n=4 for S1P- and thrombin-treated lungs; n=3 for NAC-, thrombin+NAC-, and
S1P+NAC-treatedgroups. (B) Line graph shows average decline in FDx20 fluorescence
within first 10 minutes of Ringer’s wash for each indicated treatment. Fluorescence
normalized such that “Peak” fluor. equals 1000 gray levels.
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thrombin induces an increase in S1P2 expression. In contrast, while at baseline S1P2
expression was significantly higher in EC-Cx43-/- lungs than in Cx43fl/fl mouse lungs,
thrombin treatment induces a general decrease in S1P2 expression in pulmonary
microvessels of EC-Cx43-/- mouse lungs. S1P2 signaling contributes significantly to
thrombin-induced increased microvascular permeability, and blocking S1P2 signaling
greatly attenuates that permeability increase. In addition, this is the first study to examine
whether thrombin-induced increases in ROS may be spatially expansive and shows
increases in both locally-treated and neighboring, untreated microvessels of Cx43fl/fl
mouse lungs. In EC-Cx43-/- mouse lungs, however, there was no significant increase in
ROS production with thrombin treatment compared to PBS treatment. Interestingly, this
study is the first to show that, while S1P may not affect the vascular barrier to the extent
of thrombin, S1P alone induces increases in microvascular permeability, and this affect
was mediated by the activation of S1P2 and subsequent increases in ROS generation.
The data suggests that, as has been observed in various inflammatory states and
with the treatment of inflammatory mediators, thrombin treatment induces an increase in
the expression of S1P2 in endothelial cells. In addition, thrombin induced this effect in
both thrombin-treated and –free microvessels within the Cx43fl/fl mouse lungs. This
suggests the involvement of intercellular diffusion of second messengers, as this increase
was not seen in endothelial cells or microvessels of mouse lungs lacking the major gap
junction protein Cx43. This second messenger and the specific thrombin-induced
signaling mechanism leading to this change in S1P2 expression is unclear and requires
further elucidation. Activation of the thrombin receptor PAR-1 has been shown to
activate SphK1, which subsequently leads to an increase in S1P production [63, 157]. In
turn, the S1P is exported from the cell by various ABC transporters, most notably spinster
homolog 2 (Spns2) in endothelial cells [65, 67, 71]. Following export, S1P itself has been
shown to be a second messenger and acts in a paracrine, or even autocrine, manner to
activate S1P receptors on neighboring cells [62, 70, 158-160]. In one study, treatment
with S1P was shown to cause an increase in S1P2 mRNA in a thyroid cell line [161]. In
another study, preadipocytes cultured with S1P showed a greater expression of S1P2
receptor than when not cultured with S1P [162]. It is possible that this may point to the
mechanism by which thrombin acts on S1P2 expression. PAR-1 activation leads to
increased S1P, and the S1P is exported from the cell and acts upon nearby cells to lead to
an increase in the S1P2 receptor. Interestingly, thrombin induced a greater increase in
S1P2 in thrombin-free microvessels far removed from the thrombin instillation region in
the Cx43fl/fl mouse lungs. As we begin fixing the lung surface immediately following
thrombin treatment, it could be that thrombin was already able to induce increases in both
S1P2 expression and S1P production. However, in the thrombin-treated area, the newlygenerated S1P has already had the opportunity to bind to the newly-expressed S1P2
receptors and lead to their internalization. This and other possible mechanisms by which
thrombin and/or PAR-1 activation may affect S1P2 membrane expression necessitate
further examination.
Intriguingly, basal S1P2 expression was significantly higher in endothelial cells
and microvessels of EC-Cx43-/- mouse lungs compared to Cx43fl/fl, and thrombin
treatment curiously led to a decrease in S1P2. S1P signaling is a relatively new field of
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research, and S1P has only really been seen as an important mediator within the past 15
years. There have been a few studies showing a relationship between S1P and Cx43
expression and communication, but these focus on S1P signaling and not an association
or relationship with a specific receptor. One group found that, in cardiomyocytes, S1P
treatment led to a decrease in gap junction intercellular communication by inducing
phosphorylation of Cx43 specifically at serine 368, and this effect was blocked by
inhibiting S1P2 signaling [163, 164]. On the other hand, in astrocytes S1P treatment has
also been shown to inhibit gap junction communication by dephosphorylation of Cx43
[165, 166]. In addition, in differentiating myoblasts, S1P treatment induced increases in
both Cx43 mRNA and protein levels and also increased gap junction communication
[167]. This response was dependent upon S1P activation of Ca2+- and p38-MAPKdependent pathways. However, while these studies detail the effect of S1P on Cx43, there
has been no studies exploring how Cx43 may effect S1P signaling or if there exists an
association between Cx43 and S1P receptors. In addition, there has been no
investigations as to the regulation of Cx43 function by S1P in endothelial cells. Our
results do suggest that gap junction communication itself is not involved in the intensified
expression in the knockout line as our studies in isolated mouse PMVECs used nonconfluent cells. The observed difference in S1P2 expression, both at baseline and
following thrombin treatment, in the EC-Cx43-/- mouse line adds another link in the
connection between S1P signaling and Cx43-containing gap junctions, and this
connection requires further study.
This study is the first to detail the contributions of S1P2 signaling to
microvascular permeability increases induced by thrombin. It has been determined that
S1P signaling is generally barrier protective, but this has primarily been attributed to
signaling through the S1P1 receptor [168, 169]. Using our Cx43fl/fl mouse line, we show
that under normal conditions S1P signaling did not enhance the microvascular barrier but
infact lead to a statistically significant decrease in barrier integrity, and this
hyperpermeability was prevented with the use of the S1P2 antagonist JTE-013. In
thrombin-induced microvascular hyperpermeability, blocking S1P2 signaling also
effectively blocked the increase in permeability. The effect of using JTE-013 during
thrombin treatment was quite striking and seems to suggests that, in pulmonary
microvessels, S1P2 signaling is a major factor in the induction of increased
microvascular permeability by thrombin. Following this, we wanted to explore the role of
S1P in protecting the microvascular barrier in inflammation. We treated microvessels
with thrombin and S1P, both simultaneously as well as consecutively. We observed that
while S1P given during thrombin challenge provided no benefit, there was a significant
difference in the thrombin-induced response when S1P was given following treatment
with the inflammatory mediator. These results support the conclusion that
pharmacological targeting of S1P2 may be effective in combating inflammatory
mediator-induced increases in pulmonary microvascular permeability, and suggest
delayed therapy may be more effective to particularly amerliorate hypermeability
mediated by thrombin [153, 170-172].
In addition, we explored the ability of thrombin-induced signaling to increase
ROS generation in pulmonary microvessels. Using local micropuncture instillations of
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thrombin, we observed subsequent significant increases in ROS in both thrombin-treated
and –free microvessels in Cx43fl/fl mouse lungs. Conversely, we found little to no increase
in ROS in the EC-Cx43-/- lungs. This would suggest that, indeed, increases in ROS in the
microvessels outside of the instillation area in the Cx43fl/fl lungs requires intercellular
communication. Interestingly, in both thrombin-induced increases in ROS generation as
well as S1P2 expression, the response in EC-Cx43-/- lungs was lower compared to
Cx43fl/fl lungs, even within the thrombin-treated microvessels. We observed a similar
relationship in a previous study in which thrombin-induced increases in F-actin
polymerization were less pronounced in the thrombin-treated vessels of the EC-Cx43-/mouse lungs compared to microvessels from Cx43fl/fl mice [155]. This would suggest the
involvement of intercellular communication of second messengers to see the full
response to thrombin, even in the treated areas, due to the presense of pacemaker cells
and the heterogenous distribution of membrane receptors. These results highlight the
importance of using physiological relevant models, such as IPL, to study responses in
intact tissues and organs.
We further investigated whether S1P2 may play a role in thrombin induction of
ROS generation, and found that the thrombin-induced increase that is observed in these
microvessels is dependent on S1P2 signaling. When these microvessels were pre-treated
with the S1P2 receptor blocker JTE-013 prior to thrombin, virtually no increase in ROS
was observed. Additionally, we found that, in pulmonary microvascular endothelial cells,
S1P itself induces an increase in ROS generation that was dependent on activation of
S1P2. Through subsequent permeability experiments utilizing the ROS blocker NAC, we
determined that the increase in permeability induced by S1P was due to the increase in
ROS mediated by S1P2.
Increases in ROS due to inflammatory mediators, including thrombin, have been
shown to contribute to hyperpermeability through the disruption of AJs [173]. While a
link between S1P-induced changes in ROS generation has been studied, the direct effect
of S1P receptor signaling on ROS generation is unclear, as S1P has been shown to induce
increases and decreases in ROS depending on the cell type [64]. In one study, treatment
of HLMVECs with S1P was shown to induce increases in ROS generation [174],
however the contributions of specific receptors was not investigated. In another study in
HUVECs, it was observed that treatment with high glucose concentrations increased both
S1P2 expression and ROS generation, and that blocking the increase in S1P2 was able to
subsequently block the increase in ROS production [175]. Our results here show that, not
only does signaling through S1P2 lead to increased ROS generation in lung
microvascular endothelial cells, but also that this increase is mediating the increase in
permeability induced by both S1P and thrombin.
In summary, while at baselinse microvascular endothelium lacking gap junction
protein Cx43 has a higher expression of S1P2 compared to normal, thrombin induces
increases in treated and faraway, untreated microvessels of Cx43fl/fl mouse lungs that are
absent in the EC-Cx43-/- microvessels. S1P2 signaling negatively regulates microvascular
barrier integrity both at baseline and in thrombin-induced hyperpermeability. Blocking
S1P2 was able to block the thrombin-induced increase in permeability, and S1P given
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post-thrombin treatment helped to rescue barrier integrity. S1P2 signaling was found to
mediate increases in ROS generation induced by both thrombin and S1P treatment, and it
it through this ROS increase that S1P is able to induce increases in microvascular
permeability. Similar to S1P2 expression, local thrombin treatment induced increases in
ROS generation in both treated and non-treated microvessels of Cx43fl/fl mouse lungs.
With both thrombin-induced increases in S1P2 expression and ROS production, the
response was considerably smaller in treated EC-Cx43-/- microvessels compared to those
in Cx43fl/fl, suggesting the involvement of pacemaker endothelial cells and intercellular
communication. These results demonstrate the involvement of S1P2 signaling in
hyperpermeability stimulated by inflammatory mediators, the role of intercellular
communication in thrombin-induced endothelial responses, and bring into focus the need
for physiologically relevant models to study inflammation.
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CHAPTER 5.

CONCLUSION

Summary
In the studies detailed in this dissertation, we employed the physiologicallyrelevant model of isolated perfused lungs to study signaling initiated by inflammatory
mediators. We focused on the signaling mechanisms related to the induction of increased
permeability, which in the lungs presents itself as a particularly harmful response that
may often lead to death.
In studies involving thrombin, we examined responses that have been extensively
studied in endothelial monolayers but not in actual microvessels. We studied thrombininduced responses of F-actin polymerization, ROS generation, and microvascular
hyperpermeability. We used micropuncture instillations to observe how thrombin may
trigger these effects not just in microvessels directly treated with thrombin but also in
faraway and untreated microvessels. In the case of F-actin polymerization, we found that
local thrombin application may trigger significant increases in treated microvessels as
well as microvessels up to 0.7mm away when compared to PBS instillations. Similarly,
thrombin micropuncture instillation was able to induce significant increases in ROS in
microvessels inside the treated area as well in microvessels roughly 0.6 mm outside the
instillation area, and increases in microvascular permeability itself where seen within and
outside of local thrombin treatment. These results showed that, in pulmonary
microvessels thrombin activation of PAR-1 led to spatially extensive responses such that
both microvessels directly treated with the inflammatory mediator and those far away
showed evidence of signaling that may lead to increased microvascular permeability.
We determined the role of Cx43-containing gap junctions in terms of the spatial
expansion of these thrombin responses. In endothelial-specific Cx43 knockout mice,
thrombin micropuncture instillation was unable to initiate the same degree of increase as
was seen in the floxed-control mice in F-actin polymerization or ROS generation in either
the microvessels outside the thrombin treatment site or even within microvessels directly
treated with the inflammatory mediator. In the case of microvascular permeability, the
use of the gap junction inhibitor Gap27 had no significant effect on the endothelial
integrity in microvessels in the treated site or the immediate, neighboring microvessels.
However, microvessels approximately 150 μm outside of the instillation area began
exhibiting significantly less permeability compared to thrombin alone treatment, and
microvessels approximately 300 μm outside approached PBS control values. As it is clear
that the spread of these thrombin-induced responses was dependent on intercellular
communication through Cx43 containing gap junctions, we endeavored to determine the
specific second messenger communicated and dictating these responses in the outside
microvessels. Intracellular Ca2+ concentration mediates these responses in endothelial
cells. As PAR-1 activation induces the generation of IP3, which then initiates a
subsequent increase in intracellular Ca2+, and both of these molecules may be diffused
intercellularly through gap junctions, we used the ER IP3R inhibitor XeC to curtail this
signaling. Pretreatment of all microvessels with XeC via catheter infusion blocked the
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thrombin-induced increase in F-actin polymerization, demonstrating the requirement for
IP3-induced Ca2+ release in this response. We then gave overlapping micropuncture
instillations of thrombin and XeC. In this way, if Ca2+ alone was mediating the response
in the outside microvessels, even in those treated with XeC, Ca2+ would be free to
intercellularly diffuse into this area and induce the F-actin increase. However, we
observed that focal XeC application blocked the thrombin-induced increase in F-actin
polymerization. In addition, to confirm that IP3 may be intercellularly diffused and
initiate responses in endothelial cells of intact microvessels, we used a caged-IP3
molecule (NPE-IP3) in UV photolysis experiments in which we also co-loaded vessels
with the fluorescence calcium indicator Fluo4 AM. We observed increases in Ca2+ in
microvessels within and outside of the UV uncaging site. These results demonstrate that
IP3 is the specific second messenger mediating the spatial expansion of F-actin
polymerization in pulmonary microvessels.
We also wanted to explore the relationship between thrombin- and S1P2-mediated
signaling, as well as the role of Cx43-containing gap junctions in this relationship. We
confirmed expression of the sphingolipid receptor S1P2 in cells and microvessels of both
floxed Cx43 mouse lungs as well as lungs from endothelial-specific Cx43 knockout mice.
Interestingly, we observed a significantly higher level of S1P2 expression in microvessels
from the EC-Cx43-/- compared to Cx43fl/fl. However, though we observed a dramatic
increase in S1P2 following thrombin treatment in Cx43fl/fl pulmonary endothelial cells
and microvessels, we were unable to detect similar increases in the absence of Cx43
expression. We then studied S1P2 signaling in relation to endothelial barrier integrity.
We observed that in the absence of pro-inflammatory signaling in pulmonary
microvessels, there was a major increase in microvascular permeability with S1P
treatment, and this was blocked with treatment of the S1P2 antagonist JTE-013. When
the microvessels were treated with thrombin via a microcatheter infusion, JTE-013 also
blocked the thrombin-induced hyperpermeability, and microvascular integrity remained
at control values. To determine whether S1P signaling in general may alleviate thrombininduced increases in permeability, we treated microvessels with both mediators, both
together and sequentially. We saw no difference when S1P was given with thrombin.
However, we observed a significantly lower increase in permeability when S1P was
given following thrombin infusion. We next explored possible mechanisms by which
signaling via S1P2 may mediate the permeability increase. We found that increases in
ROS generation due to both thrombin and S1P were blocked when the microvessels were
pretreated with JTE-013. Further, we found that inhibiting ROS production attenuated the
increase in permeability induced by S1P. These results showed that thrombin, like other
inflammatory mediators, initiates pro-inflammatory signaling leading to increased
expression of S1P2 at the membrane of endothelial cells. In addition, they shed light on a
previously unknown relationship between S1P and thrombin in the induction of
hyperpermeability in pulmonary microvessels.
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Future Directions
In endothelial cells, thrombin activation of PAR-1 induces change in intracellular
Ca in two phases: first through the release of ER Ca2+ stores, then a subsequent
induction of external calcium entry. These changes in cytosolic Ca2+ precede the
responses studied here, including ROS generation [9, 51]. While we show here that, like
F-actin polymerization and microvascular permeability, the thrombin-induced increase in
ROS is a spatially extensive response spreading far outside the treatment region, what is
unknown is the second messenger being communicated for this specific response. It is
probable that, like what was observed in F-actin polymerization, IP3 is the mediating
signaling molecule in this case as well. In addition to the increased ROS generation being
mediated by changes in cytosolic Ca2+ and therefore IP3, IP3 is logically the more
efficient signaling molecule. The movement of IP3 into a cell and activation of its
receptor leads to a much greater change in cytosolic Ca2+ than intercellular movement of
Ca2+ molecules alone. Thus, a similar experiment as to what was done for F-actin
polymerization, using micropuncture instillations of an IP3R blocker, would be beneficial
in making this determination.
2+

The insights gained from these experiments highlight the utility of ex vivo and in
situ models in studying inflammation in the lung. Our results showing that thrombin
induces increases in Ca2+ oscillation amplitude rather than mean Ca2+ in particular show
the differences between studying these signaling mechanisms in intact tissues versus
cultured cells. The responses induced by thrombin here were rapid, usually occurring
within 10 minutes of thrombin treatment. Key to the repair of the endothelial barrier is
the reannealing of the interendothelial junctions [176]. In addition to activation of RhoA,
thrombin-induced inactivation of Rac1 can lead to the disruption of AJs and contribute to
increased permeability. In endothelial monolayers, it has been seen that interendothelial
junctions reseal 1-2 hours after beginning sustained thrombin challenge [126]. It is
unknown, however, how sustained thrombin treatment may effect permeability of lung
microvessels. Therefore, future studies investigating the effects of a longer, sustained
thrombin treatment in pulmonary microvessels may further reveal valuable information
towards the repair of this microvascular bed following increased permeability.
In pulmonary microvessels, we observed an interesting trend in that thrombininduced responses were attenuated in the absence of Cx43, even in the directly treated
vessels. Numerous studies have already shown the effects of intercellular communication
in inflammation, including the contributions made by Cx43-containing gap junctions to
the severity of hyperpermeability and edema formation in lung inflammation [72, 73, 79,
81, 90]. However, those studies tend to look at whole monolayer or whole tissue
permeability, in which all affected cells have been treated with the permeability-inducing
agent and/or have a reduction in Cx43 expression or function, and are therefore unable to
explore spatial expansion of signaling outside of a focal treated area. These are the first
results to show that, not only does inhibiting or knocking out Cx43 seem to block the
spatial expansion of a detrimental response into untreated or healthy tissues, but also that
blocking intercellular communication affects the gravity of the response even within the
treated pulmonary microvessels. This clearly points to the therapeutic utility of limiting
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gap junctional communication in inflammation. Indeed, though not approved specifically
for lung inflammation, one such drug, carbenoxolone (CBX), is currently used to treat
gastrointestinal inflammation. In studies looking at the effects of this drug in the lung,
CBX was found to block increases in cytokine expression and infiltration of
inflammatory cells in a murine asthma model [177]. In a CLP model of sepsis and lung
inflammation, CBX blocked secretions of high-mobility group box protein 1 (HMGB1), a
late pro-inflammatory mediator and a negative indicator of survival in sepsis [178, 179].
Thus, studies that more closely examine the use of gap junction blockers in clinical
models of lung inflammation will likely show them to be beneficial towards survival.
In conclusion, our data detail: the spatially-extensive induction of responses by
thrombin that contribute to increased microvascular permeability in lung inflammation;
demonstrate the specific signaling molecule being intercellularly communicated through
Cx43-containing gap junctions for the thrombin-induced increase in F-actin
polymerization; show that S1P2 expression is affected by thrombin treatment and that
this is dependent on the presence of Cx43 in the cell; and that S1P2-mediated signaling
contributes substantially to the induction of increased microvascular permeability by
thrombin. These experiments utilized a physiologically-relevant model to study responses
that were both dependent on receptor activation by inflammatory mediators as well as
contributed to the detrimental hyperpermeability response seen in lung inflammation. The
results highlight previous work towards the importance of intercellular communication in
the spread of inflammatory responses while also providing a hereto unseen visualization
and quantification on the extent of the spread into unchallenged tissues. They also point
out a novel relationship between Cx43, thrombin, and S1P2 expression, and also the
contributions of S1P2 signaling in thrombin-induced pulmonary microvascular
disruption.
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